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Abstract 
 
Measurement of the diffusing capacity of the lung is part of the routine 
pulmonary function assessment in every patient and the single breath method is the 
most commonly used method. This method requires a subject to inspire a gas mixture 
followed by a 10 second (s) breath-hold. However dyspnoea may preclude measurement 
in patients with advanced pulmonary disease. We sought to determine if breath-hold 
time reduction had a significant effect on measured DLco values.  
Forced spirometry and CO-diffusion by the single breath method were 
performed by a respiratory scientist with a Jaeger master-screen PFT equipment, in 
duplicate with breath-holding of 10 , 8 and 6 s in 30 control subjects (FEV1 107 ± 
12.04% predicted), 30 severe COPD patients (FEV1 37.2 ± 7.92% predicted), and 30 
patients with interstitial lung disease (ILD) (FEV1 69.5 ± 17.61% predicted).  
There was no significant difference between DLcoSB and KCO measured at 10, 
8 and 6 s in the control group (p=0.4431) and ILD group (p=0.5915). However, there 
was a significant difference between DLcoSB (p=0.0003) and DLco (VA) (p=0.0183) 
measured at 10, 8 and 6 s in the COPD group. In the presence of severe airway 
obstruction the DLco decreases with breath-hold time reduction.  
In the control group and patients with ILD, there was no significant change in 
the DLcoSB when breath-hold time was reduced from 10 to 6 s. This could allow a 
reduction in breath-hold time when measuring the DLco in patients with advanced ILD 
who are unable to breath-hold for 10 s, but not in patients with severe COPD.  
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Definitions 
 
 
Anti-cholinergic: antagonist of acetylcholine drug and other muscarinic agonists. It 
blocks the muscarinic action of acetylcholine at receptors on postsynaptic membranes, 
and inhibits the response by postganglionic parasympathetic nerve activation. (Gross, 
1993) 
 
Asthma: pulmonary obstructive disease with increased responsiveness of the airways to 
different stimuli which produces an inflammation and widespread narrowing of the 
airways. It changes in severity, either spontaneously or as a result of treatment. (West, 
2008b) 
 
Β2Agonist: bronchodilator drug that combines with β2 receptors in the lung and relax 
the smooth airway muscle by increasing the adenyl cyclase activity. (West, 2008b) 
 
Bronchitis: pulmonary obstructive disease with typical excessive mucus production in 
the bronchial tree and sputum expectoration. (West, 2008b) 
 
Bronchodilators: drugs that reverse or prevent the broncho-constriction of the lung.  
(West, 2008b) 
 
Calibration: procedure that allows establishing the relationship between sensor-
determined values of flow or volume and the actual flow or volume. (Brusasco et al., 
2005) 
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CD4 helper phenotype: helper T cell with glycoprotein CD4 on the surface and 
therefore, called T4 cells. (Ganong, 1995) 
 
Capacity: composed of two or more volumes. (West, 2008a) 
 
Cystic Fibrosis: a genetic disease affecting the function of all exocrine glands with 
abnormal chloride and sodium transport. (West, 2008b)  
 
Diffusion: process by which a gas or a substance in solution expands, because of the 
motion of its particles into or out of an area in which it is present in high concentration, 
to fill all of the available volume. (Ganong, 1995) 
 
Dyspnoea: difficulty with breathing sensation. (West, 2008b)   
 
Emphysema: pulmonary obstructive disorder with typical enlargement of the air spaces 
distal to the terminal bronchiole and destruction of their walls. (West, 2008b) 
 
Fibroblasts: synthesizer cell of collagen and elastine, which are the main components of 
the interstitium in the alveolar wall. 
 
Fick’s law: “The amount of gas that moves across a sheet of tissue is proportional to the 
area of the sheet but inversely proportional to its thickness”. West (2008a) 
 
Hypoxemia: deficiency of O2 at the body tissue level. (Ganong, 1995) 
 
9 
 
 
 
Inflammatory response: localized and complex response to a foreign substance or in 
some situations to substances produced internally. (Ganong, 1995) 
 
Interstitium: space filled between the alveolar epithelium and the capillary endothelium. 
(West, 2008a) 
 
Lymphocytes: white blood cell, 2 cell type usually present in peripheral blood. (Ganong, 
1995) 
 
Methylxanthines: drug with bronchoactive and slight anti-inflammatory properties, only 
around one-fourth as potent as β2-agonists. (West, 2008b) 
 
Mitochondria: cell generating power units greater and more developed where energy 
requiring processes occurs. (Ganong, 1995) 
 
Obstructive pulmonary disorder: unbalanced reduction of the maximal airflow from the 
lung in relation to the maximal volume, leading to airway narrowing during expiration 
and is defined by an FEV1/FVC ratio reduction below the 5th percentile of the 
predicted value. (Brusasco et al., 2005) 
 
Pulmonary Hypertension: sustained elevation of the pulmonary arterial blood pressure. 
(Ganong, 1995) 
 
Non-Obstructive Pulmonary disorder: ventilatory disorder defined by a TLC reduction 
below the 5th percentile of the predicted value, and a normal FEV1/FVC ratio.  
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Shunt: blood that enters the arterial system without passing ventilated areas of the lung. 
(West, 2008a) 
 
Spirometry: method used to measure lung volume changes during a forced breathing 
maneuver.  The FVC maneuver is the most frequently performed, in which a subject 
inspires maximally and then expires as rapidly and completely possible. (Hyatt et al., 
2003) 
 
Vasoconstriction: constriction of the resistance vessels. (Ganong, 1995) 
 
Ventilation: process by the air is forced to get inside the lungs, from the airways to the 
alveoli, from where, after releasing the O2, returns saturated of CO2 being released to 
the atmosphere. (West, 2008a) 
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Glossary 
 
ATS – American Thoracic Society 
Β – Beta 
BMI – Body Mass Index 
C – Centigrade 
CaO2 – O2 concentration in the arterial blood 
CH4 – Methane 
cm – Centimetres  
CO – Carbon Monoxide 
COHb – Carboxyhaemoglobin 
COPD – Chronic Obstructive Pulmonary Disease  
CO2 – Carbon Dioxide 
CvO2 – O2 concentration on the mixed venous blood 
dl – Decilitre  
DLco – Lung diffusing capacity for carbon monoxide 
DLcoSB – Lung diffusing capacity for carbon monoxide by the Single breath Method 
DM – Membrane conductivity 
e – Electron 
ECCS – European Community for Coal and Steel 
Eqt – Equation 
ERS – European Respiratory Society 
ERV – Expiratory Reserve Volume 
ESP – Epidemiologic Standardization Project 
F – Female 
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FAco – Fraction of CO in alveolar gas 
FACO0 – Fraction of CO in alveolar gas at the beginning of the breath-hold, 
FACOT – Fraction of CO in alveolar gas at the end of breath-hold. 
FACO2 – Fractional concentration of CO in the alveolar gas 
FAHe – Fraction of He in alveolar gas 
(fb) – Frequency 
FEV1 – Forced Expiratory Volume on the first second 
FICO – Fraction of CO in the reservoir (usually 0.003) 
Fig – Figure 
FIHe – Fraction of He in the inspired gas (usually 0.10). 
FIVC – Forced Inspiratory Vital Capacity 
FRC – Functional Residual Capacity 
FVC – Forced Vital Capacity 
g – Gram 
H – Hydrogen  
H2O – Water  
Hb – Haemoglobin 
He – Helium 
Hg – mercury 
IC – Inspiratory Capacity 
IL - Interleukin 
ILD – Interstitial Lung Disease 
IPF – Idiopathic Pulmonary Fibrosis 
IR – Infra- Red  
IRV – Inspiratory Reserve Volume 
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K – Diffusion coefficient  
KCO – Transfer factor for CO 
Kg – Kilogram  
kPa – Kilopascals 
L – Litre 
Ln – Natural logarithm  
M – Male 
m2 – Square meter   
min – Minute 
MMEF – Maximum mid-expiratory flow 
ml – Millilitre  
mm – Millimetres 
mmol – Millimol 
ms – Millisecond   
N2 – Nitrogen  
O2 – Oxygen 
P – Pressure 
PaCO2 – Partial pressure of CO2 in the arterial blood 
PACO2 – Alveolar O2 pressure 
PaO2 – Partial pressure of O2 in the arterial blood 
PB – Barometric Pressure 
Pco – CO pressure 
PCO2 – Partial pressure of CO2 
PO2 – Partial pressure of O2 
PECO2 – Expired CO2 pressure 
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Pred – Predicted 
Q – Blood flow per unit time 
R – Respiratory exchange ratio 
RV – Residual Volume 
s – Seconds 
SD – Standard Deviation 
STPD – Standard temperature (273 K, 00C), pressure (101.3 kPa, 760 mmHg) and dry 
T – Breath-hold interval 
Th0 - The T-lymphocytes 
Th1 - T-helper type 1 cells 
Vc (theta) – Reaction rate (specific uptake of CO by the blood) 
TLC – Total Lung Capacity 
VA – Alveolar Volume 
VA – Alveolar ventilation 
VA/Q – Ratio of ventilation to blood flow 
VC – Vital Capacity 
Vc – Pulmonary capillary blood volume 
VD – Dead space 
VD/VT – Ratio of dead space to tidal volume 
VE – Ventilation 
V/Q – Ventilation/Perfusion ratio 
VT – Tidal Volume 
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Background 
 
The human respiratory system is made up of gas exchanging organs which are 
the lungs and a pump that ventilates the lungs. The pump consists of the chest wall, the 
respiratory muscles (which increase and decrease the size of the thoracic cavity), areas 
in the brain that control these respiratory muscles and the tracts and nerves that connect 
the brain to the muscles. The respiration of a subject can be assessed by pulmonary 
function testing, described as the process of having a subject performing specific 
inspiratory and expiratory manoeuvres while breathing in and out of tubing attached to 
equipment that measures a variety of variables. These tests allow the evaluation of the 
respiration of a subject and assessment of any abnormality, as well as to quantify it. 
There are a wide range of pulmonary function tests measuring lung volumes, gas 
exchange in the lungs or evaluating respiratory muscle function.    
Pulmonary function tests are designed to identify and quantify defects and 
abnormalities in the function of the respiratory system. They can answer questions like 
how badly impaired is the patient lung function, if a patient has impaired gas exchange 
in the lung or if a treatment is of benefit. Although the majority of these procedures are 
non-invasive, they require cooperation from the subject and expertise from the 
respiratory technician. Measurement of the diffusing capacity of the lung involves the 
subject inhaling a low concentration of carbon monoxide (CO) and a tracer gas to 
determine gas exchange within the lung. Several methods of evaluating CO diffusion 
are available, but the single breath technique (DLcoSB) is the most commonly used. 
This method is called the single breath technique because the CO diffusion in the human 
lung is measured during a 10 seconds (s) breath-hold by a subject. 
16 
 
 
 
The main disadvantage of the single breath method is that not every subject is 
able to hold their breath for 10 s in order to measure lung diffusion. Shortening breath-
hold time might allow for completion of the test in subjects with more severe 
respiratory impairment as clinical experience shows that longer breath-hold times lead 
to difficulties in cooperation in many patients. Based on limited published data on the 
effect of breath-hold time reduction in lung diffusion measurement, we decided to 
investigate if the values obtained with a shorter breath-hold time are significantly 
different from conventional measurements to assess human lung diffusion capacity. 
This study will investigate if the reduction of breath-hold time in the  
single-breath CO diffusion measurement has a significant effect on measured DLcoSB 
in healthy subjects, patients with severe chronic obstructive pulmonary disease (COPD) 
and patients with interstitial lung disease compared with conventional measurements. 
17 
 
 
 
Chapter 1 
 
INTRODUCTION 
 
1.1 Aim of the Study 
 
We sought to determine if breath-hold time reduction in the single-breath CO 
diffusion measurement has a significant effect on measured DLcoSB values in control 
group, patients with severe chronic obstructive pulmonary disease (COPD) and patients 
with interstitial lung disease (sarcoidosis with interstitial fibrosis or idiopathic 
pulmonary fibrosis (IPF)) compared with conventional measurement using ATS/ERS 
standards. Demonstration of theb absence of a significant difference associated with 
breath-hold time reduction can potentially lead to a change in guidelines for breath-hold 
time during DLcoSB measurements and can thus increase the number of patients in 
whom DLcoSB can be measured, particularly for those who are unable to breath-hold 
for 10 s. 
 
1.2 Anatomy and Physiology of the Lung 
 
 The airways of the lungs consist of a series of branching tubes which become 
narrower, shorter and more numerous as they penetrate deeper into the lung. Their 
function is to lead inspired air to the gas exchanging regions of the lung. The trachea 
divides into right and left main bronchi which in turn divide into lobar, then segmental 
bronchi, down to the terminal bronchioles. The bronchioles are the smallest airways 
18 
 
 
 
making up the conducting airways with no alveoli and therefore constitute the anatomic 
dead space of the lung, where no gas exchange occurs. The terminal bronchioles divide 
into respiratory bronchioles which lead to the alveolar ducts and alveoli where gas 
exchange occurs. This area is known as the respiratory zone of the lung and accounts for 
2.5-3 L of volume during rest. 
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Fig. 1.1 
Idealization of the human airways according to Weibel (1963),  
accessed 2 April 2012, http://www.comprehensivephysiology.com 
The figure shows a model of the human airway system divided by generations of symmetric 
branching from trachea (0) to acinar airways (15–23), ending in alveolar sacs. The first 16 
generations make up the conducting airways, and the last 7, the respiratory zone (or the 
transitional and respiratory zones). 
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 The airways systematically divide over an average of 23 generations of 
dichotomous branching, as described by Weibel (1963), ending eventually in a blind sac 
(figure 1.1). The last nine generations of these airways are connected to tightly packed 
alveoli, airways chambers in which gas exchange takes place, whereas the central 
airways serve the function of conducting the air to the gas-exchange parenchyma. 
According to Fishman (2007), the gas exchange parenchyma can be divided in 
two units: the lobes and the acini. There are three lobes on the right (upper, middle and 
lower) and two on the left (upper and lower), which are separated by the pleura. The 
acini begin with a transitional bronchiole and terminate with alveoli and are defined as 
parenchymal units which and participate in gas exchange. 
The main mechanism of ventilation in the respiratory zone, illustrated in figure 
1.2, is the diffusion of respiratory gases and the rate of diffusion of gas molecules within 
the airways is so rapid, as well the distances to be covered so short, that “differences in 
concentration are virtually abolished within a second”. (West, 2008a)  
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Fig 1.2  
Gas diffusion in the alveolar-capillary membrane,  
accessed 2 April 2012, http://medical.tpub.com/10669-c/css/10669-c_56.htm 
The alveoli are thin, microscopic air sacs within the lungs, in direct contact with 
the pulmonary capillaries. At this level the gas exchanges occurs in the lung. 
 
The pulmonary blood vessels show a characteristic relationship to these 
structural respiratory units, following the airway course through the centre of the units 
and finally ending in the capillaries located in the alveolar septa of lung parenchyma. 
This pulmonary blood vessels form a series of branching tubes from the pulmonary 
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artery into the capillaries and back to the pulmonary veins. As shown in figure 1.3, the 
pulmonary capillaries form a dense network around the alveoli, allowing for efficient 
gas exchange. (West, 2008a)  
 
 
 
Fig. 1.3  
Pulmonary Circulation stratification,  
accessed 04 April 2012, http://www.78steps.com,  
The blood is pumped from the heart right ventricle, it enters the pulmonary artery. This 
artery splits and takes blood to each lung. In the lungs, the blood passes through sacs 
called alveoli where gas exchange occurs.  
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Airflow occurs both by mass flow (laminar, turbulent or transitional airflow) and 
by diffusion. Mass flow occurs in the larger airways whilst diffusion occurs in the 
alveolar ducts and sacs. As the cross-sectional area of the airways increases, the velocity 
of the airflow decreases. 
 
1.3 Measurement of Lung Volumes and gas exchange of the Lung 
 
1.3.1 Static and Dynamic Lung Volumes 
 
 Static lung volumes and capacities (composed of two or more volumes) are an 
excellent tool to assess human lung function. The total lung capacity (TLC) is the 
maximum volume of air in the lungs after a maximal inspiratory effort. The volume of 
air that remains in the lungs after maximal expiration (the residual volume (RV)) cannot 
be measured directly.  
Volume between TLC and RV, the vital capacity (VC), can be measured directly 
as can other volumes like the expiratory reserve volume (ERV) and inspiratory reserve 
volume (IRV). The tidal volume (VT) and IRV will constitute the inspiratory capacity 
(IC), which also is the difference between the TLC and the functional residual capacity 
(FRC). The FRC is the volume of air remaining at the end of a normal tidal expiration. 
(Cooper et al., 2011) 
Figure 1.4 illustrates the different static volumes and capacities of the lung. 
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Fig. 1.4 
Scheme of static lung volumes and capacities,  
accessed 4 April 2012, http://www.cybermedicine2000.com,  
The diagram shows the changes in volume (on the vertical axis) against time (on the horizontal 
axis) as a subject breathes, initially tidal volumes, and then inspires and expires maximally. 
 
When changes in volume or flow with respect to time are recorded, dynamic 
volumes are obtained. If a subject takes a maximal breath to TLC exhaling forcibly to 
RV and then inhales back to TLC, the forced vital capacity (FVC) and forced inspiratory 
vital capacity (FIVC) can be measured during the expiratory and inspiratory 
manoeuvres respectively. A series of variables can be obtained from this recording with 
respect to time, the most valuable of which is the forced expiratory volume in the first 
second (FEV1). It has been reported by Cooper et al. (2011) that “on average a normal 
subject can exhale about 80% or more of the FVC in the first second of a full 
exhalation”. They also suggest that the measurement of the FEV1 and FVC has a 
number of applications, such as determining if lung disease is present and quantifying 
the degree of impairment. 
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Lung volumes can be measured and recorded directly using a volume measuring 
spirometer which electronically reproduces the volume signal with respect to time to 
obtain the flow, allowing the construction of volume-time and flow-volume curves as 
illustrated in figure 1.5.  
 
Fig. 1.5 
Volume-time and flow-volume loop,  
accessed 4 April 2012, http://blog.ert.com/2011/04/29/spirometry 
Spirometry is one diagnostic test for pulmonary mechanics, which measures the inhalation and 
exhalation of air over time and represented by spirograms: flow volume loop (A) and volume 
time curve (B). 
 
 
The flow-volume curves are measured directly using a flow measuring 
pneumotachograph and the shape of the flow volume curve assists in the recognition of 
different types of respiratory impairment. 
Before performing pulmonary function tests the patient’s age, height, weight and 
sex must be obtained for the calculation of reference values, as lung volumes are related 
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to body size, with height as a major correlating factor. Reference equations for 
spirometry are obtained from cross-sectional studies and both the European Community 
for Coal and Steel (ECCS) and the American Thoracic Society (ATS) have published 
reference equations for spirometry. (Brusaco et al., 2005) Combined reference equations 
published by Quanjer et al. (1993) are often used in Europe for people aged 18-70 years 
old, with a height range of 155-195 cm in males and 145-180 cm in females. 
 
1.3.2 Ventilation 
 
 
Ventilation (VE) is the process by which air is drawn into the lungs and gas from the 
alveoli is expelled, allowing gas exchange. In this process, oxygen (O2) is absorbed in 
the pulmonary circulation and carbon dioxide (CO2) released from the blood into the 
alveoli. The primary function of ventilation is to facilitate gas exchange. VE is the 
movement of air between the atmosphere and the alveoli and can be calculated from 
breathing frequency (fb) and VT using the equation: 
          Eqt. 1.1 From Cooper et al., 2011. 
 
The total volume of air breathed by a subject per minute and the portion of 
volume that reaches the alveoli, called alveolar ventilation, must be differentiated. 
Alveolar ventilation (VA) is the volume of gas that effectively participates in gas 
exchange and is always less than total ventilation. The anatomical dead space, which is 
the volume of air in the conducting airways that does not participate in gas exchange, 
represents the difference between total and alveolar ventilation. (Cooper et al., 2011) 
The lung volume that is ventilated but not perfused by pulmonary capillary 
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blood flow constitutes the respiratory dead space (VD) and can be divided into: the 
conducting airways (anatomic dead space) and the non-perfused alveoli (alveolar dead 
space). The total volume of air breathed by a subject per minute (total ventilation) can 
be measured directly by having the subject breathing through a valve box that separates 
the inspired from the expired gas, and collects all the expired gas in a bag. (Ruppel, 
1994) 
However, the VA cannot be measured directly and one method to determine is by 
measuring the volume of the anatomic dead space and calculates the dead space 
ventilation using the following equation 1.2: 
      Eqt 1.2 From Ruppel, 1994. 
 
In atmospheric gas, the CO2 concentration is almost zero, so the VA can be 
calculated also based on CO2 elimination from the lungs. In this method, a volume of 
expired gas is collected in a bag and analysed to determine the volume of CO2 and VA 
calculated by the following equation:   
           Eqt. 1.3 From Ruppel, 1994. 
 
  
In equation 1.3 the VCO2 is the volume of CO2 produced in litres per minute and 
the FACO2 is the fractional concentration of CO in alveolar gas. 
The volume of air in the conducting airways that does not participate in gas 
exchange is called anatomic dead space, usually approximately 150 ml that can be 
increased by large inspirations due to the traction or pull exerted on the bronchi by the 
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surrounding lung parenchyma. This anatomic dead space can also depend on the size 
and posture of the subject. One of the methods used to measure VD is the Fowler’s 
method, where a subject breaths a nitrogen concentration following a single inspiration 
of oxygen (West, 2008a) as shown in fig 1.6. 
 
Fig 1.6 
Fowler’s method,  
accessed 4 April 2012, http://www.tzhealth.com,  
The figure shows a N2 analyzer monitoring continuously the N2 concentration of gas being 
inspired or expired. During inspiration, the N2 analyzer records 80% N2 in inspired and expired 
gas. The subject will take a deep breath of O2 and followed by a slow breathe out.  During 
inspiration, the N2 analyzer records 0% N2.  At the beginning of expiration, about 50 ml of pure 
O2 is expired (phase I). In phase II about 200 to 300 ml of N2 concentration rises, which 
represents the washout of the remainder of the dead space gas by alveolar gas, and then at last 
by pure alveolar gas (phase III). At phase IV, the N2 concentration of the expiration end rises 
because of the progressive closure of the small airways at the bases of the lungs.   
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The principal of this method is to measure volume in the conducting airways 
until dilution of inspired gas occurs with gas already in the lung. The volume measured 
will depend on the geometry of the rapidly expanding airways, reflecting the 
morphology of the lung airways. 
 Another way of measuring the dead space is the Bohr’s method using the 
Bohr’s equation (Eqt. 1.4). Since the expired CO2 comes mainly from alveolar gas and 
not from dead space and also because the alveolar concentration of CO2 is difficult to 
determine, the partial pressure is used and the equation 1.4 is written as follows: 
                                                      
         Eqt. 1.4 From Cooper et al., 2011. 
 
In equation 1.4, A and E refer to alveolar and mixed expired, respectively. The 
normal ratio of dead space to tidal volume (VD/VT) is from 0.2 to 0.35 at rest. 
According to Ruppel (1998) this method measures the volume of the lung that 
does not expel CO2 and the volume measured is called physiologic dead space. In 
normal subjects the anatomic and physiological dead space are almost the same but in 
patients with pulmonary impairment, the physiological dead space may be larger 
because of ventilation / perfusion mismatch in the lung. Therefore, the measurement of 
physiological dead space represents a useful index of ventilation-perfusion in the lung 
since all CO2 in expired gas comes from perfused alveoli. The VD/VT ratio will reflect 
the volume of ventilation not used in the conducting airways and poorly perfused 
alveoli. The VD measurement provides important information regarding the ventilation-
perfusion characteristics of the lungs, increasing with increased VT during exercise and 
decreasing with bronchial obstruction or mucous plugging. West (2008) states: “lower 
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regions of the lung are better ventilated than the upper regions because of the effects of 
gravity on the lung”. 
 
1.3.3 Perfusion 
 
 
The pulmonary circulation begins with the pulmonary artery, which collects 
mixed venous blood from the right ventricle. The pulmonary artery branches 
successively like the bronchial tree into the pulmonary arteries and arterioles following 
the airways to the terminal bronchioles. These arterioles supply the capillary network in 
the walls of the alveoli, forming a dense network in the alveolar wall as illustrated in 
figure 1.7 and establishing an efficient surface for gas exchange.  
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Fig. 1.7  
Alveolar circulation,  
accessed 4 April 2012, http://www.uic.edu,  
The bronchi branch into smaller tubes called the bronchioles and then to small gas exchange 
units know as alveoli, covered by the smallest blood vessels, the capillaries. 
 
 Oxygenated blood is collected from the capillaries by small pulmonary veins 
that will unite to form four large veins that drain into the left atrium of the heart. The 
pulmonary circulation pressure is much lower compared with the systemic circulation. 
The systemic circulation is responsible for the supply of blood to various body organs 
and by contrast the pulmonary circulation accepts the entire cardiac output. The 
pressure at the pulmonary capillaries is unknown as they are surrounded by gas and they 
collapse or distend depending on the pressures within and around them. The pressure 
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difference between the inside and outside of the capillaries is called the transmural 
pressure. 
During inspiration when the lungs expand, larger blood vessels like the 
pulmonary arteries and veins are pulled open by radial traction of the elastic lung 
parenchyma decreasing the pressure around them. Alveolar capillaries are exposed to 
alveolar pressure and their calibre is determined by the relationship between alveolar 
pressure and the pressure within them. (West, 2008a) 
The extra-alveolar vessels include all the blood vessels that run through the lung 
parenchyma. These vessels are exposed to a lower pressure compared to the alveolar 
pressure and are pulled by the radial traction of the surrounding parenchyma of their 
walls. The lung volume constitutes an important determinant of pulmonary resistance. 
During deep inspiration, alveolar pressure rises compared to capillary pressure and the 
blood vessels will be compressed and therefore their resistance rises. Also the calibre of 
these pulmonary capillaries will depend on lung volume, decreasing at larger lung 
volumes due to stretching and thinning of the alveolar walls. 
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Fig. 1.8 
Four zone model of pulmonary circulation,  
accessed 4 April 2012, http://www.coheadquarters.com 
The human lung is about 30 cm tall from apex to base therefore gravity exerts an important role 
in determining blood flow direction in the lung. The human lung can be divided into 4 zones 
represented by the figure 1.8 above. The hydrostatic arterial and venous pressures fall with 
increasing distances up the 30 cm height of the lung where: a=arterial, A=alveolar and 
V=venous. 
 
The lung of an adult is around 30 cm from apex to base and gravity is a 
significant factor in determining blood flow in the lung. The lung can be divided into 4 
zones of perfusion as shown in figure 1.8, illustrating that the hydrostatic blood pressure 
is highest at the base and lower at the apex. 
The four zone model presented in figure 1.8 shows that the arterial and venous 
pressures at the apex may both be less than the air pressure inside the alveoli and this 
will interrupt the blood flow as the air pressure decreases and closes the blood vessels. 
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Often, there is very little, if any, blood flow in zone 1. At zone 2, the arterial pressure is 
higher than alveolar pressure but the venous pressure is less than alveolar pressure and 
the blood flow, instead of being determined by the usual arterial-venous pressure 
difference, is determined by the arterial-alveolar gradient. Arterial pressure increases in 
zone 2 due to gravity, while alveolar pressure remains relatively constant and so the 
arterial-alveolar difference increases in zone 2 and thus blood flow increases from the 
top to the bottom of this zone.  
In zone 3, the arterial and venous pressures exceed alveolar pressures and here 
blood flow will be determined by the arterial-venous difference. In this zone of the lung, 
both arterial and venous pressure increase due to gravity and the pulmonary blood 
vessels distend leading to decreased resistance. Also the pulmonary blood flow will rise 
from the top to the bottom of zone 3. 
Finally, at zone 4 at the base of the lung, the ratio of ventilation to blood flow is 
low and consequent alveolar hypoxia leads to compensatory vasoconstriction, limiting 
local blood flow. When the alveolar pO2 is reduced, hypoxic pulmonary 
vasoconstriction occurs through contraction of smooth muscle in the walls of small 
pulmonary arterioles. The primary function of hypoxic pulmonary vasoconstriction is to 
direct blood flow away from hypoxic regions of the lung. These hypoxic regions may 
arise from airway obstruction and this diversion of blood flow reduces the effects on gas 
exchange. West (2008a)   
According to West (2008a) this mechanism remains obscure in spite of a great 
deal of research. 
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1.3.4 Ventilation – Perfusion 
 
 
The relationship between ventilation and blood flow is a major determinant of 
pulmonary gas exchange. The four scenarios of impairment of gas exchange that result 
in hypoxemia are: hypoventilation, diffusion impairment, shunt and ventilation-
perfusion mismatch. West (2008b) defines hypoxemia as an abnormally low pO2 in 
arterial blood, with the normal value between 11 and 13 kPa. The pO2 in the alveolar 
gas depends on a balance between two processes: pulmonary capillary blood capacity 
for the O2 absorption and its continued replacement by alveolar ventilation. The rate at 
which O2 is absorbed from the lung is determined by its consumption by the body 
tissues and is almost constant at rest. Alveolar pO2 is greatly determined by the level of 
alveolar ventilation. If alveolar ventilation is decreased, the alveolar pO2 decreases and 
the pCO2 increase due to hypoventilation. If hypoventilation is present, the pCO2 
increases until a steady state has been achieved and the alveolar and arterial PO2 
decreases, except when the subject breaths an O2 mixture that compensates for reduced 
ventilation. (West, 2008b)  
Diffusion impairment means that the pO2 in the pulmonary capillary blood and 
alveolar gas are not balanced. In some pulmonary diseases, the alveolar-capillary 
membrane is thickened and diffusion is decreased to the point that equilibration may be 
incomplete, due to a slower time course for diffusion. The presence of pulmonary 
diseases, such as interstitial lung diseases where the diffusion path from alveolar gas to 
red blood cell may be increased, may be affect time for oxygenation. (West, 2008b) 
Another factor that can decrease the arterial pO2 in relation to alveolar level is the 
presence of shunted blood. According to West (2008) shunt refers to blood that enters 
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the arterial system without being previously in ventilated areas of the lung. 
Intrapulmonary shunts can be caused as well by arterial-venous malformations, often 
with genetic basis. The hypoxemia induced by a shunt cannot be corrected by 
administering 100% O2 because according to West (2008b) “the shunted blood that 
bypasses ventilated alveoli is never exposed to the higher alveolar pO2, so it continues 
to depress the arterial pO2”.  
The intrapulmonary shunts can be divided in true shunt and shunt-like effect. In 
a true shunt, blood flows from the right to the left side of the heart without contacting an 
alveolus for gas exchange (perfusion without ventilation). A true shunt can be classified 
as an anatomic or a capillary shunt and the main difference is their origin. Anatomic 
shunts can be normal when the shunted blood comes from veins such as bronchial, 
pleural, or thebesian veins, and abnormal when shunted blood arises from congenital 
heart disease, pulmonary arteriovenous malformations or vascular lung tumours. 
Capillary shunts are caused by alveolar collapse (atelectasis), alveolar fluid 
accumulation (pulmonary oedema) and alveolar consolidation (pneumonia). As 
anatomic and capillary shunts are true shunts, the associated hypoxia cannot be treated 
by increasing the inspired O2 concentration. 
In the shunt-like effect, the blood exchanges gas with alveolar gas but the pO2 
does not reach the pO2 of normal alveoli. This type of shunt can be caused by 
hypoventilation (bronchospasm or excessive mucus in the tracheobronchial tree) and 
alveolar-capillary membrane impairment such as in patients with pulmonary fibrosis, 
where diffusion does not have enough time to occur. 
The ventilation-perfusion inequality is characterized by mismatch of ventilation 
and blood flow in various regions of the lung leading to an impaired gas transfer. In this 
process, both O2 and CO2 transfer results will be impaired and this is the main 
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mechanism of hypoxemia in diseases such as chronic obstructive pulmonary disease, 
interstitial lung disease and vascular disorders. The ventilation-perfusion inequality is 
commonly identified by excluding the other three causes: hypoventilation, diffusion 
impairment and shunt. (West, 2008b)  
The O2 concentration in the human lung is determined by the ratio of ventilation 
to blood flow (VA/Q) by the following equation (which also applies to CO2, N2 and any 
other gas present under steady-state condition). The equation is as follows: 
 
     Eqt. 1.5 From Cooper et al., 2003. 
Where: 
• Q is the blood flow per unit time, 
• R is the respiratory exchange ratio,  
• CaO2 the O2 concentration in the arterial blood,  
• CvO2 the O2 concentration on the mixed venous blood,  
• PaCO2 the partial pressure of CO2 in the arterial blood. 
 
If the VA/Q of the lung unit is decreased by airway obstruction, the O2 
concentration will decrease and the CO2 will rise, and if the ventilation is completely 
ceased, this ratio will reach zero. On the other hand, if this ratio increases by impaired 
perfusion, the O2 concentration will increase and the CO2 will fall, and also if the blood 
flow ceases, will reach the composition of the inspired gas.  
Regional gas exchange patterns are defined by the VA/Q, being high at the apex 
of the lung and much lower at the base. If pulmonary disease is present, this regional 
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pattern will disappear and at the alveolar level the normal relationships between 
ventilation and blood flow will be perturbed. Although ventilation-perfusion inequality 
will reduce the gas exchange efficiency of the lung for all gases, in many cases a normal 
pCO2 may occur because ventilation will be increased in the alveoli. However, the pO2 
is always low and so the alveolar-arterial pO2 difference is a useful measure of 
ventilation-perfusion inequality. (West, 2008b) 
 
1.3.5 Diffusion Capacity of the Lung 
 
Oxygen travels along the airways from the mouth into the alveoli by bulk 
movement of air (movement of air from a region of high pressure to one of low 
pressure) and diffusion occurs by movement of a gas when a pressure gradient in the 
alveoli is present. Diffusion of gases in the lung occurs by molecular movement that 
increases as temperature rises and occurs over a short distance of about 1mm, between 
the alveolar duct and the alveolar capillary membrane. (Cooper et al., 2011) The O2 
must cross the alveolar capillary membrane before entering the erythrocytes, moving 
from the gas phase to the liquid phase. Oxygen has to diffuse through pulmonary 
surfactant, the alveolar epithelium, the interstitium, the capillary endothelium and then 
the plasma before reaching the erythrocyte membrane and finally combining with 
haemoglobin. The blood will carry O2 to the body tissues where it diffuses through the 
plasma, capillary endothelium, interstitium and the mitochondrial membrane. The 
reverse process will occur for CO2. (Cooper et al., 2011) According to West (2008a) 
“the diffusion of a substance in fluids (liquids or gases) is a passive process occurring 
between regions of differing gases concentrations. If a membrane of constant thickness 
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and permeable to a particular gas is placed between two fluid compartments, the 
diffusion of a gas across the membrane is described by Fick’s law of diffusion which 
states that the rate of transfer of a gas through a sheet of tissue is proportional to the 
tissue area and the difference in gas partial pressure between the two sides, and 
inversely proportional to the tissue thickness” (West, 2008a). The following equation 
1.6 is Fick’s Law of diffusion and allows the calculation of the diffusion of a gas. 
        Eqt. 1.6 From Cooper et al., 2011. 
                                                                                                                                            
 
In the equation 1.6, K is the diffusion coefficient and P1 – P2 the difference of 
the gas partial pressure. The larger the surface area (A), the higher will be the difference 
in pressure and the thinner the membrane (t), the higher will be the rate of diffusion as 
illustrated in figure 1.9. 
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Fig. 1.9 Fick’s law of diffusion,  
accessed 4 April 2012, http://www.elu.sgul.ac.uk 
The O2 diffuses from a place of higher partial pressure (P1O2, e.g. the alveolar air) to one of 
lower partial pressure (P2O2, e.g. the pulmonary capillary) through a membrane of area A and 
thickness X. 
 
 
The density and solubility of a gas will also determine the diffusion rate. 
Oxygen, which is less dense than CO2, diffuses about 1.2 times faster under same 
conditions in the alveoli. However, their relative solubility changes when crossing the 
alveolar-capillary membrane, as CO2 in the liquid phase is about 24 times more soluble 
than O2, and therefore CO2 diffuses about 19 times faster than O2. (Cooper et al., 2011)  
Oxygen travels easily across the alveolar capillary membrane combining with 
haemoglobin (Hb). Initially, this movement will depend on a pressure gradient between 
alveoli and capillaries for O2 which continues to diffuse from alveoli to capillary blood 
until Hb becomes saturated with O2. At this point the O2 pressure rises and equilibrates 
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with alveolar O2 pressure (PAO2). If the thickness of the alveolar-capillary membrane 
increases, O2 diffusion is impaired and the rate of rise of oxygen partial pressure (pO2) 
is reduced. If a severe abnormality is present, the pO2 may not reach the pO2 of alveolar 
gas. (Cooper et al., 2011) The rate of diffusion will therefore depend of the physical 
properties of the alveolar-capillary membrane, as the surface area and thickness of the 
membrane will determine the rate of diffusion. The surface area for diffusion can be 
altered by changes in lung volume and in pulmonary artery pressure.  
The Hb molecule has a major role on the gas transport and diffusion given its 
large capacity for O2, as each Hb molecule can transport four O2 molecules, releasing 
O2 when needed. Hb is also involved in CO2 and hydrogen ion transport. The 
combination of O2 with Hb can be illustrated by the Oxyhaemoglobin dissociation curve 
in figure 1.10 and is only possible due to changes in the structure of the Hb molecule. 
(Cooper et al., 2011)  
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Fig. 1.10  
Oxyhaemoglobin dissociation curve 
From Cooper et al., 2011 
The Oxyhaemoglobin dissociation curve is a graph that shows the percent saturation of Hb 
various partial pressures of O2. The main goal of the dissociation curve is to show the 
equilibrium of oxyhaemoglobin and nonbonded  Hb at various partial pressures.  At high partial 
pressures of O2, Hb binds to O2 to form oxyhaemoglobin.  
 
The sigmoidal shape of the Oxyhaemoglobin dissociation curve is the result of 
chemical reactions that occur between O2 and each haem group of the Hb molecule. 
This curve shifts position but the sigmoid shape is preserved. (Cooper et al., 2011) 
Figure 1.10 illustrates the percentage of haemoglobin that reacts with O2 at each 
O2 pressure. Oxygen rapidly combines with haemoglobin as the pO2 rises but around 60 
mmHg, despite of increase of pO2 there is minimal increase in the oxygen-haemoglobin 
binding as Hb is already 90% saturated. At the flat portion of this curve, the pO2 in the 
blood can drop from 100 to 60 mm Hg and the Hb will remain 90% saturated with O2 
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and wide changes in pO2 only will produce a small variation in the oxygen saturation 
(SaO2). Even after most of the O2 is transferred, significant partial pressure difference 
appears to exist between the alveolar gas and the blood, as blood continues to flow 
through the alveolar-capillary system which facilitates O2 diffusion across the alveolar-
capillary membrane.  
There are other factors that will shift the O2 dissociation curve. If the pH 
decreases this curve will shift to the right (decreased affinity) caused by a rise of pCO2 
as CO2 moves into the blood from the cells, helping the unloading of O2. In the opposite 
scenario, an increase of pH will shift the curve to the left (increased affinity), caused by 
decreased pCO2 as CO2 moves from the blood into the alveoli, increasing the loading of 
O2 in the lungs and decreasing the unloading of O2 at the tissues. Temperature is another 
important factor affecting binding of the O2 with the Hb. An increase in temperature 
will shift the curve to the right (decreased affinity), enhancing the unloading of O2 and 
decreasing the loading of O2 in the lungs. In the other hand, a decrease in temperature 
will shift the curve to the left (increased affinity), increasing the loading of O2 in the 
lungs. 
The CO2 concentration in the blood will also affect the Oxyhaemoglobin 
dissociation curve. An increase in CO2 will shift the curve to the right (decreased 
affinity) because an increase of the partial pressure of arterial carbon dioxide (PaCO2) 
leads to an increase in hydrogen ion concentration. This will enhance the unloading of 
O2 in actively metabolizing tissues like muscles during exercise and decrease loading of 
O2 in the lungs. A decreased CO2 will shift the curve to the left (increased affinity), 
caused by decreased pCO2 as CO2 moves from the blood into the alveoli, as well as 
enhancing the loading of O2 in the lungs and reducing the unloading of O2 at the tissues. 
Finally the 2,3-Diphosphoglycerate (2,3-DPG), a substance that is formed by the red 
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blood cells during anaerobic glycolysis will shift the curve to the right (decreased 
affinity) if its concentration rises, as O2 will be released more efficiently at the tissues. 
This scenario can be caused by hypoxia, anaemia and pH increase. On the other hand, 
decreased 2,3-DPG will shift the curve to the left (increased affinity), enhancing the 
loading of O2 in the lungs and decreasing the unloading of O2 at the tissues. 
The diffusing capacity of the lung is measured using carbon monoxide (CO) and 
referred to as DLco. The DLco is used to assess the lungs gas exchange, measuring the 
transfer of CO across the alveolar-capillary membrane. The CO affinity to bond with Hb 
is approximately 210 times more than O2 and with normal Hb concentration and normal 
ventilatory function, the major limiting factor to CO diffusion is the integrity of the 
alveolar-capillary membrane. CO concentration in pulmonary capillary blood is 
normally very low or inexistent and therefore the pressure gradient causing diffusion is 
effectively the alveolar pressure. Consequently, a small amount of CO in inspired gas 
will produce changes in the concentration of inspired versus expired gas that can be 
measured and if the partial pressure of CO in the alveoli and the rate of uptake of the 
gas can be measured, the DLco of the lung can be determined. (West, 2008a) 
The diffusion properties of the alveolar membrane depend on its thickness and 
area. The diffusion is also reduced when the surface area of the blood-gas barrier is 
reduced. In obstructive diseases such as emphysema, the reduction in diffusing capacity 
is partly due to destruction of alveoli and capillaries. The rate of combination of CO 
with Hb is reduced when the number of red cells in the capillaries is low and also in 
diseases that limit the capillary blood volume. (West, 2008a) 
The diffusing capacity of the lung for the CO can be measured by three methods: 
the single-breath method (which is the most commonly used), the Clarke Rebreathing 
method and the Intra-breath method. The single breath method will be further discussed 
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in this paper, as it was the method used in this study to assess lung diffusion. In the 
single-breath method, a subject takes a VC breath of CO and He, holds their breath for 
10 s, and then exhales to RV. The first 750 ml are discarded because of dead space, and 
the next litre is collected and analysed. Another gas, helium (He), is used as a tracer gas 
and facilitates assessment of the dilution of the inspired gas (CO) to obtain the initial 
alveolar CO pressure (Pco). According to West (2008), CO is absorbed from alveolar 
gas proportionate to the Pco during a breath-hold; thus, the diffusing capacity can be 
calculated as the volume of CO taken up per minute per mmHg alveolar Pco. (West, 
2008a) 
The advantages of this method include standardization by the ATS/ERS task 
force (MacIntyre et al., 2005), good reproducibility and reference values available. 
Disadvantages are the fact this measurement is performed at TLC, leading to difficult 
patient co-operation and also a minimum of 1.3 litres VC is required. The rebreathing 
method is a simple technique that requires a 1 litre anaesthetic bag to which the patient 
is connected and the gas mixture is the same as that used for the single-breath method. 
At the end of a normal tidal breath, a tap is turned and the subject breathes in and out 
only from this bag, emptying it each time, at a rate of 10 breaths in 10 s. The 
rebreathing time is recorded from a stopwatch and the contents of the rebreathing bag 
are then analysed and the alveolar gas concentrations recorded. The major advantage of 
this method is for patients who are unable to perform the breath-hold technique because 
lung volumes are too small as no VC is required. However, this method also depends of 
the patient co-operation and few reference values are available.  
The third and last method to measure CO diffusion in the lung is called intra-
breath and is a variation on the single-breath breath-holding method mentioned above. 
There is no breath-hold and the subject inhales the test gas mixture of CO and CH4 
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(Methane) from RV to TLC and then exhales gradually until RV is reached. The major 
advantage of this technique is the lack of requirement for a minimum VC, although no 
standardization for this measurement exists and only few reference values are available. 
(Cooper et al. 2011)  
Therefore, the single-breath breath-holding method is the most commonly used 
to access the DLco of the human lung. 
 
1.3.6 Historic Development of DLcoSB measurement 
 
 
The use of CO to measure diffusion capacity was introduced by Christian Bohr in 1909 
when he reported that the affinity of Hb for CO was greater than the affinity of Hb for 
O2. He also reported that even if small concentrations of CO in alveolar gas were used, 
the back pressure of the carboxyhaemoglobin (COHb) in the pulmonary capillary blood 
could be ignored. (Cooper et al., 2011)  
In 1915 August and Marie Krogh (Forster et al. 1954) introduced the idea that 
the CO was transferred to the alveolar space by diffusion alone and they designed a 
measuring method which included a period of breath-holding. Krogh asked subjects to 
inhale a VC breath of CO as two alveolar samples were collected, and while the first 
sample was collected during an immediate exhalation to about ½ VC, obtaining the CO 
concentration at the beginning of the breath-hold, the second sample was collected after 
six to ten seconds of breath-hold measuring the CO final concentration.  
For the determination of the VA, the dilution of hydrogen method was applied, 
where the end volumes of the two expirations represented the alveolar gas and were 
analyzed for CO concentration. To Krogh the CO concentration fell exponentially and 
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could be calculated by the following equation 1.7. 
 
     Eqt. 1.7 From Forster 
et al., 1954. 
In the above 1.7 equation the FA is the alveolar concentration of CO at time t, 
representing the final sample; the FA0 is the alveolar concentration at time zero, the 
initial sample; the “exp” is e; the base of the natural logarithms, raised to the power 
contained in the brackets following: D ids the pulmonary diffusing capacity for CO; VA 
is the total alveolar gas volume during the period of breath-holding; t is time in seconds 
between the delivery of the two gas samples; and Pb is the total barometric pressure 
minus 47mmHg. In this equation (Forster et al. 1954) the CO concentration on the first 
sample was representative of all alveolar gas and that the CO tension in the pulmonary 
capillary plasma (Pc) could be ignored. However, Roughton (1945) reported later that 
Pc should be considered.  
The Krogh equation describes diffusion of CO into the blood for time of breath-
holding during apnoea: 
 
             
Eqt. 1.8 From Qutayba, A. Shannon, J. Martin, J. 2005. 
 
Later Forster et al. (1954) suggested the addition of He to the Krogh method and 
also the reduction to a single gas collection at the end of a known period of breath-
holding. (Forster et al., 1955)  
In 1957, a similar paper was published by Olgivie et al. (1957) which 
incorporated all the modifications mentioned by Forster and standardized the technique 
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for the single-breath DLco method. Ogilvie proposed the elimination of the first 
alveolar sample by adding He, an inert gas, to the mixture test gas and standardized the 
DLcoSB measurement, still in use currently, where subjects rapidly inhale a test gas 
mixture containing CO, He, O2 and N2 from RV to TLC. After a 10 second breath-hold, 
subjects exhale again to RV. The major modification introduced by Ogilvie was the 
parallel measuring of He dilution to estimate the concentration of CO at the onset of 
breath-holding. In this technique all the alveolar gas was collected except the first litre 
(used to washout the VD) and breath-hold time was measured from the start of 
inhalation (t0) to the beginning of the sample collection (t1).  
Jones and Meade (1961) realized that Krogh equation was valid only for the 
breath-hold time portion during apnoea in the Ogilvie method (Ogilvie et al. 1957). 
Errors in the CO diffusion measurement could be minimized by measuring the breath-
hold time from 3/10 of the time of inhalation to the time for one-half of the alveolar 
sample collection, and also by collecting a smaller alveolar gas sample. (Qutayba, A. 
Shannon, J. Martin, J. 2005)   
Modifications of Ogilvie’s method to calculate DLcoSB are the current methods 
in use and VA is measured from the single breath dilution of He as proposed by 
McGrath and Thompson (1959) as shown by the equation 1.9.  
 
                                      
Eqt. 1.9 From Qutayba, A. Shannon, J. Martin, J., 2005. 
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1.3.7 Respiratory Gas Analysis 
 
 
Analysis of respiratory function involves the measurement of gas concentrations 
where precise measurements are crucial and the analyzer used should provide a rapid, 
accurate, linear, stable and specific response to the gas being analysed. How fast an 
analyzer detects a change in the gas concentration is an important factor. In order to 
produce a feasible measurement of gas concentration at any instant in time, the response 
of the analyzer should be preferably of 100ms or greater. (Cooper et al., 2011) Figure 
1.11 illustrates the delay time and response time of a gas analyzer. 
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Fig. 1.11  
Definition of delay time and response time of a gas analyser, 
From Cooper et al., 2011. 
The delay time is defined as the amount of time it takes for a sample to reach the  
analyzer, and is the time taken by the gas to travel from the sampling end to the  
entrance of the analyser. The delay time is represented by the straight line portion 
 of the response time graph.  During the delay time, the response time graph remains 
 flat, since no gas has yet reached the analyser. As soon as the test gas sample enters 
 the sample chamber, the gas begins to rise and this will mark the rise time of the 
 curve. The response time is the delay caused by transit time and rise time. In the 
 response time graph, rise time is the time required for the displayed value to rise 
 from the baseline to the maximum value. 
 
 
To design and construct a gas analyser, the physical properties of gases are taken 
into account and consequently a variety of gas analysers exist. In respiratory function 
testing, the accuracy of the gas analyser of respiratory gases can be affected by the 
presence of other gases in the sample, typical examples being water vapour and CO2. 
Water vapour will dilute the gas to be analysed and should be removed from the sample. 
CO2 is removed by granules containing barium hydroxide or sodium hydroxide, also 
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called soda lime. (Cooper et al., 2011)  
Analyzers used to measure CO gas diffusion in the lung are an Infra-Red or an 
Electro-chemical type analyzer. In the Infra-Red analyzer, infra-red radiation is 
absorbed by gases such as CO2 and CO in proportion to their concentration. A single 
element coil with a filter will constitute the IR source, so that only the wavelength to the 
gas being analysed is emitted. Since CO and the CO2 have close IR absorption bands, 
the presence of one in the sample being analysed will interfere with the analysis of the 
other. This interference can be minimized by the use of a filter tube manufactured to the 
optical pathway. (Cooper et al., 2011) 
CO can also be analysed using an electrochemical sensor as shown in figure 
1.12, which consists of a sealed fuel cell with an aqueous electrolyte containing a 
sensing and reference electrode with a constant voltage supplied by a battery. CO will 
diffuse into the cell oxidising at the platinum anode according to the equation 1.10: 
      
Eqt. 1.10 From Cooper et al., 2011. 
Where e
-
 is an electron and at the reference electrode the reaction is describe by 
equation 1.11: 
                   
Eqt. 1.11 From Cooper et al., 2011. 
 
The flux of e
-
 resulting from this electrochemical reaction is recorded and is 
directly proportional to the partial pressure of CO. In contrast to the IR analyzers, the 
electrochemical ones are not affected by CO2 and only filters for water and alcohol 
vapour are used. Each time the analyzer is used, a full scale calibration is performed 
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with air and a CO/air mixture. (Cooper et al., 2011) 
 
Fig. 1.12 
Diagram of the fuel cell for electrochemical analysis of CO. 
From Cooper et al., 2011 
The fig. represents a sealed fuel cell with an aqueous electrolyte with  
sulphuric acid containing a platinum sensing electrode and reference electrode with a constant 
0.15 voltage supplied by a battery. 
 
 
Another gas analysed during lung diffusion assessment is He which is measured 
by a thermal conductivity analyzer. This type of analyzer measures the rate at which 
heat is conducted by a gas, the thermal conductivity of a gas. The thermal conductivity 
of He is much higher compared with other respiratory gases. This type of analyzer 
consists of a Wheatstone bridge compromising four resistances with a constant given 
bridge current, so that the temperature and the resistance remain constant. Of these four 
resistors, one is the reference cell sealed with a gas of known concentration or exposed 
to atmosphere and one the measuring cell. If the Helium concentration changes in the 
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reference cell, the temperature and resistance in the measuring cell will change - more 
heat is conducted and the resistance will fall, proportional to the He concentration 
change. Thermal conductivity analyzers are stable, linear, calibrated at zero with air and 
contain a CO2 and water vapour absorber through which the sample being analysed 
passes. (Cooper et al., 2011) Calibration should be performed daily or before the 
analyzers are used, the readings recorded in a logbook and the minimal requirement to 
obtain a quality test is a two point calibration: a zero point and a full scale deflection. 
 
1.3.8 Diffusing capacity for CO by the Single Breath Method 
 
 
The single breath breath-holding measurement is based on the measurement of 
CO uptake over a short period of time by the estimated difference of the partial pressure 
between the alveoli and the pulmonary capillary blood. 
Measurement of the diffusing capacity of the lung by the single breath method 
requires a mixture containing the actual test gas, CO and an inert gas that allows 
alveolar volume assessment, He. He is a stable gas that is almost inactive and relatively 
insoluble and therefore is called the tracer gas due to its chemical properties. He is used 
to determine the CO initial concentration, as well as the VA. Diffusion of the tracer gas 
should be similar to the transfer gas (CO), not interfere with the measurement of CO 
concentration and also be absent in alveolar gas. In this method the subject inspires a 
vital capacity breath from a system with a spirometer containing a gas mixture of 0.3% 
CO, 10% He, 21% O2, and the balance N2. First, the subject exhales completely to RV 
and then inhales the gas mixture and holds breath at TLC for 10 s. Before the breath-
hold, a valve opens allowing exhalation to the spirometer and a sample of alveolar gas 
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is collected in a bag, after the washout volume is discarded, as illustrated in figure 1.13. 
The washout volume contains gas from the anatomical and instrumental dead space and 
should be about 750 to 1000ml, unless the VC of the subject is less than 2000 ml in 
which case the washout volume should be reduced to 500ml. The instrumental VD 
represents the mouthpiece, filters and connections within the valve system, and should 
be specified by the manufacturer. The anatomical VD is the volume of the conducting 
airways that are not involved in gas exchange and the most commonly used formula for 
its calculation is by the equation 1.12. 
       
Eqt. 1.12 From MacIntyre et al., 2005. 
 
Alveolar gas sample contamination with VD gas may interfere with measured 
CO uptake. Therefore, its correct estimation is particularly important, as He 
concentration in expired gas will indicate the effective dilution of the inspired gas with 
the alveolar gas and give the initial alveolar CO pressure. (Ruppel, 1998) 
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Fig 1.13 
Trace obtained during the single breath breath-hold transfer factor measurement.  
Trace shows the inspired volume breath-hold time, washout and sample volumes. 
From Cooper et al., 2011 
  
The DLcoSB method assumes that both CO and He are similarly diluted in 
inspiration. The sample collected is analysed and the fractional CO and He 
concentrations in the alveolar gas obtained. The equation 1.13 illustrates how the initial 
concentration of CO is calculated: 
                      
Eqt. 1.13 From Cooper et al., 2011. 
Where: 
 FICO is the fraction of CO in the reservoir (usually 0.003); 
 FIHe the fraction of He in the inspired gas (usually 0.10); 
 FACO0 is the initial CO concentration in the alveoli at the 
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beginning of the breath-hold; 
 FAHe the fraction of He in alveolar gas. 
The variation of the He concentration will predict dilution by gas remaining in 
the lungs and allow the assessment of the FACO0 before any gas is diffused from the 
alveoli into the pulmonary capillaries.  
The DLcoSB is calculated by Krogh’s standard equation 1.14: 
        
Eqt. 1.14 From Ruppel, 1998. 
 
Where: 
 VA is alveolar volume, ml (STPD),  
 60 is correction from seconds to minutes, 
 PB is the barometric pressure, mmHg, 
 47 is the water vapour pressure (PH2O) at 37°C, mmHg, 
 T the breath-hold interval, seconds, 
 Ln the natural logarithm, 
 FACO0 the fraction of CO in alveolar gas at the beginning of the 
breath-hold, 
 FACOT the fraction of CO in alveolar gas at the end of  
breath-hold. 
If abnormal distribution of inspired volume is present, such as in airway 
obstruction, poor gas mixing can occur and this can reduce the transfer gas dilution and 
thus lead to a lower measured VA value.  
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There are several methods of measuring the breath-hold time, which estimates 
the time of contact between the test gas mixture and the red cells during gas exchange. 
In order to standardize its measurement, the ATS/ERS guidelines (MacIntyre et al., 
2005) recommend the Jones and Meade method (Jones and Meade, 1961) of the three 
available methods described in figure 1.14, in which “the breath-hold time equals the 
time starting from 0.3 of the inspiratory time to the middle of the sample collection time 
and the time when 90% of the inspired volume is achieved”. (MacIntyre et al., 2005) 
The other two methods are the Olgivie method (Olgivie et al., 1957) that measures the 
breath-hold time from the beginning of inspiration to the beginning of alveolar sample 
collection and the Epidemiologic Standardization Project (ESP) that measures the 
breath-hold time from the time of 50% of inspired volume (VI) is achieved to the 
beginning of alveolar sample collection.  
According to Ruppel, the DLco measured with the ESP method might be higher 
if breath-hold time starts at the midpoint of VI. Similarly, some diffusion occurs during 
washout and alveolar sampling if, as in the Jones and Meade method, the breath-hold 
time period is extended into the alveolar sampling phase and the real time of breath-hold 
is increased and the additional diffusion measured. (Ruppel, 1998) 
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Fig. 1.14  
Schematic illustration of different methods of measuring  
breath-hold time for the DLcoSB. From MacIntyre et al., 2005 
The method by OGILVIE(–) measures breath-hold time from the beginning of inspiration to the 
beginning of alveolar sample collection. The method by JONES and MEADE(----) includes 
70% of inspiratory time and half of sample time. 
The Epidemiologic Standardization Project (– – – –) measures breath-hold time from 
the time of 50% of VI to the beginning of alveolar sample collection. The time of inspiration (tI) 
defined from the back-extrapolated time 0 to the time that 90% of the VI has been inhaled. 
 
The breath-hold time should be measured by an accurate timing device able to 
measure 100ms over a 10 second interval. Most modern computerized systems time the 
breath-hold automatically. (Ruppel, 1998)  
In order to standardize the DLCO measurement some precautions should be 
taken. According to the ATS/ERS task force guidelines (MacIntyre et al., 2005), the 
interval between tests should be at least 4 minutes and in patients with obstructive lung 
disease up to 10 minutes, which will allow an adequate washout of test gas from the 
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lungs. Also, the patient should remain seated during this time.  
MacIntyre et al. (2005) emphasises that some considerations must be taken 
before measuring DLcoSB such as diurnal variation in DLco, ingestion of ethanol 
(reported to decrease DLco) and administration of bronchodilators before the test (may 
increase DLco by up to 6%). Also supplemental oxygen should not be administered at 
least 10 minutes before test. Subjects should refrain from smoking 24 hours before the 
test (time of the last cigarette smoked should be noted), as smoking is a major source of 
carboxyhaemoglobin and may lead to a reduction in measured DLco reduction, due to 
effects on CO back pressure that decrease the Hb available to combine with CO from 
the test gas. (MacIntyre et al., 2005) At least two acceptable tests should be recorded 
and meet the repeatability criteria of “either being within 3 ml CO (STPD) · min-1 · 
mmHg
-1
 of each other or within 10% of the highest value” in order to obtain an accurate 
DLco measurement. The acceptability test criteria for DLCOSB measurement, according 
the ATS/ERS guidelines, are the use of quality-controlled equipment, an inspired 
volume of at least 85% of the higher VC in less than 4 s, no evidence of leaks, a stable 
breath-hold for 10 s, an expiration of less than 4 s with sample collected in less than 3 s 
and sufficient VD clearance. 
Whether Hb should be standardised, in normal subjects or patients, for DLcoSB 
measurement is still being debated, as the cost of measuring Hb in every patient during 
routine clinical assessment is high in relation to the small improvement in accuracy of 
the measurement. According to Cooper et al. (2011) unless the Hb concentration is < 
11.0 g.dl
-1
 or > 18 g.dl
-1
, correcting the Hb for each DLcoSB measurement will add a ± 
5% difference. For that reason, Hb correction should be applied in conditions where the 
Hb concentration is expected to be low or changing. The standard Hb value is assumed 
to be 14.6g
.
dl
-1
 in adult males and adolescents and 13.4g.dl
-1 
in adult females and 
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children < 15 years old, but equations 1.15 for adult males and 1.16 for adult females 
and children <15 years old can be used for adjusting the DLco predicted: 
 
      
Eqt. 1.15 From MacIntyre et al., 2005 
     
Eqt. 1.16 From MacIntyre et al., 2005 
 
CO diffusion depends mainly on two conductance properties which are the rate 
of combination of CO with Hb, expressed as the product of the CO-Hb reaction rate (θ) 
and the volume of Hb in alveolar capillary blood (Vc); and the membrane conductivity 
(DM) which predict the diffusion properties of the alveolar capillary membrane. Several 
physiological and pathological processes can affect DM, θ and Vc and interfere with the 
DLCO. (MacIntyre et al., 2005) Conditions such as respiratory muscle weakness and 
thoracic deformity that can lead to a reduction in lung inflation (which consequently 
reduces VA) will decrease effort and produces changes in DM, θ or Vc reducing DLCO. 
Also, diseases like anaemia and pulmonary emboli, as well as Hb binding changes and 
the Valsalva manoeuvre can reduce θ and Vc and thus reduce DLCO. Lung resection, 
emphysema, interstitial lung disease, pulmonary oedema, pulmonary vasculitis and 
pulmonary hypertension reduce DM, θ and Vc and thus reduce DLCO. Other conditions 
and diseases can increase θ and Vc and increase DLCO, as such polycythaemia, left-to-
right shunt, pulmonary haemorrhage, asthma, Hb binding changes, the Muller 
manoeuvre, exercise, the supine position and obesity (possible DM component). 
(MacIntyre et al., 2005)  
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Diseases that are associated with abnormally increased alveolar-capillary 
membrane thickness, such as interstitial lung disease, lead to a reduction in the diffusing 
capacity of the lung and it is also reduced when the surface area of the blood-gas barrier 
is reduced, such as after a pneumonectomy. In emphysema, low diffusing capacity of 
the lung is caused by the destruction of alveolar walls and capillaries (West, 2008b). 
Thus, DLco measurement is a useful tool for the clinical assessment, diagnosis and 
management of both obstructive and restrictive pulmonary disorders (Ruppel, 1998).  
The degree of severity of decrease in diffusing capacity for carbon monoxide is 
defined by the ATS/ERS guidelines (Brusasco et al., 2005) as mild where DLcoSB and 
KCO% predicted are between the lower limits of normal and above 60%, moderate 
where DLcoSB and KCO % predicted are between 40 and 60% and severe where DLco 
and KCO% predicted are below 40%.  
The DLcoSB reflects the uptake of CO per unit pressure difference between the 
alveoli and pulmonary capillary and if the CO diffusion within the lung is normal, 
abnormalities of DLco suggest disease at alveolar level. The KCO, also called transfer 
factor, attempts to correct alterations in the VA of the subject, due to an inadequate 
inspiration to TLC during DLco measurement in normal lungs or with maximal 
inspiration in the presence of respiratory disorders that reduce the VA. The measured 
DLco is divided by the VA during CO diffusion measurement. According to Brusasco et 
al. (2005) when “the KCO is multiplied by the volume of gas in the lung containing CO 
(alveolar volume), the total uptake of CO by the lung per unit of time per unit driving 
pressure is obtained, this product being termed the transfer factor of the lung (KCO)”.  
Interpreting DLco and KCO requires an understanding of normal physiology and 
of pathophysiological effects of the disease being assessed. The predicted reference 
values for VA, DLco and KCO should be used from the same source and factors that 
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interfere with DLco and KCO measurement should be considered when interpreting the 
results. The most commonly used predicted reference values equations for DLcoSB 
calculations are those from 1993 ERS document. (Jones and Meade, 1961) 
 
1.4 Abnormalities of Gas Exchange in Human Lung 
 
1.4.1 Chronic Obstructive Pulmonary Disease 
 
According to the ATS/ERS task force (Celli et al., 2004), chronic obstructive 
pulmonary disease (COPD) is a “preventable and treatable disease state characterised by 
airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and is associated with an abnormal inflammatory response of the lungs to 
noxious particles of gases, primarily caused by cigarette smoking”. COPD commonly 
produces pathological changes in four different compartments of the lungs: the central 
airways, peripheral airways, lung parenchyma and pulmonary vasculature, and despite 
being primarily a disease of the lungs, can also lead to significant systemic effects.  
(Celli et al., 2004)  
COPD is an umbrella term for a combination of emphysema and chronic 
bronchitis (peripheral airway obstruction). Emphysema is characterized pathologically 
by alveolar wall destruction which leads to enlargement of airspaces and loss of lung 
elasticity, obstruction of peripheral airways and destruction of the capillary bed. Chronic 
bronchitis is characterized by peripheral airways obstruction due to inflammation and 
excessive mucus production by hypertrophy of mucous glands. The abnormal amount of 
mucus in the airways may obstruct some of the small bronchi. (West, 2008b) Airway 
obstruction in patients with COPD will increase resistance to the airflow. Loss of radial 
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traction from destruction of the lung parenchyma will also cause airway narrowing, 
particularly in the peribronchial region of the airways. 
The increase in airflow resistance in COPD will amplify the effect of the static 
recoil pressures reduction on the normal pressure gradient between the alveoli and the 
mouth. The loss of elastic recoil and excessive contraction of abdominal muscles will 
decrease intraluminal pressures during expiration, leading to airway collapse. This can 
be summarized in fig. 1.15 where an equal pressure point model is used. 
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Fig. 1.15 
Model illustrating pleural pressures,  
accessed 4 April 2012, http://flylib.com/books 
Equal pressure point model where static recoil pressure is +10 cm H 2 O.  
In scenario A (static conditions) no flow is present and the forces of elastic recoil and chest wall 
recoil are balanced. As forced expiration occurs in presence of airway obstruction in scenario B 
(Dynamic conditions), the thoracic pressure becomes positive, frictional pressure losses within 
the airway occur reducing the intraluminal pressure. When the critical point is reached, airway 
collapse may occur and despite further increases in intrathoracic pressure, expiratory flow will 
remain constant. 
 
In this diagram a critical pressure point occurs in the airway where the 
expiratory flow is independent of any extra applied pressure, explaining the typical 
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expiratory flattening of the flow-volume loop in COPD obtained by spirometry (Fig. 
1.16). This explains why the FEV1 and the FEV1/FVC ratio assessment are of great 
importance in COPD patients. 
Figure 1.16 demonstrates why patients with severe COPD achieve maximum 
expiratory flow during tidal breathing, reducing their capacity to increase ventilation 
without increasing either lung volumes or inspiratory work. 
 
 
Fig. 1.16 
COPD flow volume loop,  
accessed 4 April 2012, http://www.spirometrie.info/fvc.html 
The air in the large airways can be expired without problems, so the PEF is will be normal. 
When all the air is expired from the large airways, the air from the smaller airways will be 
expired partially blocked and will come out slower and in a lower flow creating a sharp fall in 
the flow-volume. 
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The inflammatory response in COPD is caused predominantly by cigarette 
smoking. An important feature of COPD pathogenesis is the imbalance of proteinases 
and antiproteinases in the lungs, and oxidative stress. (Celli et al., 2004)  
Hyperinflation is another important feature of COPD and that leads to a 
significant elastic load to breathing, which becomes important as flow resistance 
increases. Shortening of the diaphragm length can occur, changing the muscles fibre 
orientation and leading to impairment of contraction. Also geometric changes will make 
the development of tension harder to achieve. All these respiratory muscles changes will 
increase the total work of breathing and oxygen consumption by respiratory muscles. 
The loss of vertically oriented diaphragm muscles fibres, the increased work of the 
pectoral muscles as accessory respiratory muscles, and the use of abdominal muscles 
during expiration contribute to increased work of breathing in COPD. (Gross, N. 1993) 
Farkas et al. (1983) reported that the respiratory muscles may adapt to the chronic 
hyperinflation by a compensatory reduction in sarcomere numbers.  
The diagnosis of COPD should be considered when symptoms of cough, sputum 
production, dyspnoea or a history of exposure to risk factors for the disease are present. 
Diagnosis requires confirmation of airflow obstruction by spirometry. If spirometry 
after bronchodilator shows an FEV1/FVC ratio ≤ 0.7, the presence of airflow limitation 
is confirmed, which in COPD case is not fully reversible. The Global Initiative for 
Chronic Obstructive Lung Disease guidelines (Lenfant, C. Khaltaev, N. et al., 2003)  
define COPD severity by a post-bronchodilator FEV1/FVC ≤ 0.7 and mild COPD 
represented by FEV1 ≥ 80% predicted, moderate COPD by FEV1 50-80% predicted, 
severe COPD by FEV1 30-50% predicted and very severe COPD by FEV1 < 30% 
predicted. (Celli et al., 2004)  
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Three types of bronchodilator are commonly used for management of COPD: β2-
agonists, anticholinergic drugs and methylxanthines. Despite differences in their site of 
action in the airways, the most important effect of bronchodilator therapy is airway 
smooth muscle relaxation and lung emptying during tidal breathing. Figure 1.17 
illustrates the different types of bronchodilators and their site of action. 
 
 
Fig. 1.17 
Mechanisms of action of bronchodilators on airway smooth muscle,  
accessed 4 April 2012, http://www.medscape.com 
The anticholinergics act by blocking the effect of acetylcholine on muscarinic receptors (M1, 
M2 and M3). Anticholinergics disassociates slowly from the muscarinic receptors, providing 
bronchodilation. Beta-2 agonist drugs bind to beta-2 receptors on airway smooth muscle and 
lead to an increase in the concentration of cAMP (cyclic adenosine monophosphate) in the 
muscle cell which results in smooth muscle relaxation. When airway smooth muscle relaxes, the 
diameter of the air passages is increased. Theophylline blocks the action of phosphodiesterases 
and prevents the breakdown of cAMP to AMP (adenoside monophosphate). This also has the 
effect of relaxing smooth muscle and allowing the airways to dilate.  
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The FEV1 change in COPD after a bronchodilator is typically small but can 
produce larger changes in lung volumes, thus reducing RV and hyperinflation. (Celli et 
al., 2004) 
The DLcoSB is often reduced in COPD, as emphysema reduces the lungs 
surface area by loss of both alveolar walls and their associated capillary beds. The main 
consequence is less gas transfer per minute even if the remaining gas exchange units are 
structurally normal. The path length from the terminal bronchiole to the alveolar-
capillary membrane in emphysema can be increased and gases must cross farther to 
reach the alveolar-capillary surface. Airways collapse and gas trapping also produces 
ventilation-perfusion abnormalities. (Ruppel, 2008) 
Ventilation-perfusion inequality in COPD is caused by the disorganization of the 
lung architecture in emphysema causing hypoxemia with or without CO2 retention. 
Respiratory failure in COPD can occur in 2 settings: moderate hypoxemia with normal 
arterial pCO2 (Type 1 respiratory failure), or severe hypoxemia with an increased pCO2, 
typically seen in more advanced disease (Type 2 respiratory failure). A high alveolar–
arterial pO2 difference is always present (especially in severe bronchitis). VD is also 
increased in emphysema. Destruction of the capillary bed causes uneven ventilation as 
well as regional inequality of blood flow. However, impaired gas exchange and V/Q 
inequality can be minimised by collateral ventilation (physiologic communicating 
channels that exist between adjacent alveoli and between small airways) and hypoxic 
vasoconstriction, a local response to low alveolar pO2 that reduces blood flow to poorly 
ventilated areas. (West, 2008) 
Despite V/Q inequality, arterial pCO2 can be normal in mild to moderate COPD, 
but as severity progresses, the arterial pCO2 may increase. An important factor is the 
increased work of breathing but also reduced sensitivity of the respiratory centre to 
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CO2. The rise of pulmonary artery pressure in COPD as severity progresses contributes 
to V/Q inequality as portions of the capillary bed are destroyed, increasing vascular 
resistance and hypoxic vasoconstriction.  (West, 2008b) 
Physiologically significant changes in pulmonary circulation occur with disease 
progression in COPD. The normal pulmonary circulation has great capacitance with low 
vascular resistance, due to its ability to recruit additional capillary beds. Gross et 
al.(1993) reported that in patients with COPD at rest, the mean pulmonary artery 
pressure increases by “the loss of capillary bed due to emphysema, changes in blood 
viscosity due to polycythaemia, altered alveolar oxygen tension due to a V/Q inequality, 
or raised intrathoracic pressures”. Polycythaemia occurs due to daytime and/or 
nocturnal hypoxia which can worsen with continued cigarette smoking (Calverley et al., 
1982). In advanced COPD, severe pulmonary hypertension can occur, reducing the 
cardiac output.   
 
1.4.2 Sarcoidosis 
 
 
Sarcoidosis is defined by Fishman (2007) as a “multisystem disorder of 
unknown origin aetiology characterized by noncaseating granulomatous inflammation 
at sites of disease that frequently presents with bilateral hilar lymphadenopathy, ocular 
and skin lesions”. Although any organ can be involved, this disorder predominantly 
involves the lungs and lymph nodes. The diagnosis of sarcoidosis is frequently 
established from clinical and radiologic findings, in combination with demonstration of 
noncaseating epithelioid granulomas in affected organs and exclusion of other causes of 
granulomatous disease. (Fishman, 2007) 
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Although the cause of sarcoidosis is still uncertain, it is thought that genetically 
susceptible hosts develop sarcoidosis when exposed to specific environmental agents. 
This concept, as reported by Hunninghake et al. (1999), is supported the fact that the 
inflammatory response present in sarcoidosis is characterized by activated macrophages 
and CD4 helper T lymphocytes that lead to a profile of cytokine production that is 
consistent with a Th1-type immune response triggered by an antigen. Fishman (2007) 
states that clinical, epidemiologic, and family studies strongly suggest that exposure to 
microbial agents when a genetic susceptibility is present can trigger sarcoidosis.  
Sarcoidosis occurs between 20 and 40 years in 80% of cases, but also is seen in 
women > 50 years. (Fishman, 2007) The course and prognosis of sarcoidosis may relate 
to the pattern of onset of the disease. Sarcoidosis that presents acutely with erythema 
nodosum and bihilar lymphadenopathy commonly shows a self-limiting course, and by 
contrast, a more insidious onset is more likely to lead to progressive fibrosis of the 
lungs. (Hunninghake et al. 1999) 
The characteristic pathologic feature in sarcoidosis is the presence of 
noncaseating epithelioid cell granulomas composed of differentiated mononuclear 
phagocytes and lymphocytes. Commonly, sarcoidosis granulomas are located in lymph 
nodes (especially intra-thoracic), lungs, liver, spleen and skin. These granulomas can 
resolve spontaneously, or produce fibrotic damage, which can lead to parenchymal 
fibrosis of the lung. (Hunninghake et al. 1999)  
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Fig. 1.18  
Pathogenesis of Sarcoidosis, 
 accessed 4 April 2012, http://highered.mcgraw-hill.com 
The normal alveoli represented in the top and the alveoli in active sarcoidosis in the bottom. 
The latter are distorted by the accumulated CD4&plus; TH1 lymphocytes, alveolar 
macrophages, and macrophages aggregated into granulomas. There is mild damage to 
alveolar epithelial and endothelial cells. 
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Figure 1.18 shows how alveoli in active sarcoidosis may be damaged by 
accumulated CD4+ Th1 lymphocytes, alveolar macrophages, and macrophages 
aggregated into granulomas. The trigger origin for the Th1 lymphocytes is uncertain but 
according to Hunninghake et al. (1999), a limited class of antigens or self-antigens 
presented in the context of class II HLA surface molecules by mononuclear phagocytes 
to the Th1 lymphocyte may be causal. Increased production of inflammatory mediators 
such as TNF-alpha, IFN-gamma, and IL-12 is present. The antigen class II HLA 
complex is identified by the T cell antigen receptor, and the T cell is activated. As a 
result, Th1 lymphocytes will release IL-2, which causes activation of more T 
lymphocytes. Macrophage inflammatory proteins and granulocyte-macrophage colony-
stimulating factor contribute to granuloma formation. The diagnosis of pulmonary 
sarcoidosis is based on finding stable formed granulomas surrounded by lymphocytes 
and fibroblasts in a perilymphatic interstitial distribution with no alternative cause.  
In sarcoidosis the lungs are commonly affected, and in 30-50% of cases, 
dyspnoea, dry cough and chest pain may occur. Pulmonary sarcoidosis is frequently 
staged by radiographic findings, as reported by Hunninghake et al. (1999) Five chest 
radiographic stages can be defined: stage zero, with no visible intrathoracic findings; 
stage one where bilateral hilar lymphadenopathy is present, together in some cases with 
paratracheal adenopathy; stage two with hilar adenopathy and parenchymal infiltration; 
stage three with parenchymal infiltration without hilar adenopathy; and the last, stage 4 
with advanced fibrosis and “honey-combing”, hilar retraction, bullae, cysts and 
emphysema. Grutters et al. (2009) stages sarcoidosis based on data from patient studies, 
interpreted in the context of experimental models of immune responses and in this 
model, three stages are mentioned:  
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 Stage one, involves the exposure to present unknown exogenous or endogenous 
antigenic proteins taken by the antigen cells and processed into peptide 
fragments. These peptides are loaded by an histocompatibility Class II  
molecules and taken to the T-Cell receptors of the T-lymphocytes ( Th0). The Th0 
is activated and polarised as T-helper type 1 cells (Th1) under the influence of a 
interleukin (IL). 
 Stage two, is characterised by a granuloma formation due to an ongoing 
presentation of antigen by the lung macrophages to the Th1 cells. These will start 
a well organized production of chemokines and cytokines by the Th1 cells which 
leads to a high demand, migration and retention of cells such as T-lymphocytes 
and macrophages. All these cells organize into immune granulomas, usually 
non-necrotising. 
 Stage three, will involve the evolution of the granulomatous inflammation that 
can resolve spontaneously or persist leading to a chronic course of disease and 
the onset of a fibrotic response. This fibrotic process may lead to end-stage 
sarcoidosis marked by parenchymal fibrosis and honeycombing pattern. 
 
Commonly, pulmonary function is normal in stages zero and one of the disease, 
but in stages two and higher, a non-obstructive ventilatory defect can be found. In this 
setting, lung volumes will be decreased except for the FEV1/FVC ratio which is normal 
as classified by the British Thoracic Society (Bellamy, 2005) and presented in table 1.1. 
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Spirometry Parameters Non Obstructive Disorders 
FEV1 < 80% predicted normal 
FVC < 80% predicted normal 
FEV1/FVC ratio Normal (> 0.7) 
 
Table 1.1 Spirometry Classification for non obstructive disorders 
 
The Figure 1.19 illustrates a typical non-obstructive flow volume loop. 
  
Fig. 1.19 
Non-obstructive Flow Volume loop,  
accessed 4 April 2012, http://courses.washington.edu 
The shape of the flow volume loop is relatively unaffected in restrictive disease, but the overall 
size of the curve will appear smaller when compared to normal on the same scale. 
Similarly, there will be a rapid upslope on the volume time curve, but such patients will reach a 
smaller vital capacity. 
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Furthermore, in stages two or three the DLcoSB and KCO can be impaired. The 
pO2 at rest may be low and can decrease significantly with exercise. The pCO2 can be 
normal or low, but will rise in advanced stages. (West, 2008b) 
 
1.4.3 Idiopathic Pulmonary Fibrosis 
 
Idiopathic Pulmonary Fibrosis (IPF) is the most common cause of interstitial 
lung disease and its cause is uncertain. IPF is characterised by a specific combination of 
clinical, radiographic and pathological findings that lead to a progressive dyspnoea, 
hypoxemia and ultimately death. The IPF incidence increases with age; two-thirds of 
cases occur over the 60 years with a mean of 66 years at diagnosis. (Fishman, 2007) 
Usually, IPF presents with gradual onset of cough and dyspnoea. Dyspnoea is 
progressive and commonly reported for more than 6 months before diagnosis. IPF is 
defined by Ruppel (1998) as a “specific form of chronic fibrosing interstitial pneumonia 
limited to the lung and associated with the histologic appearance of usual interstitial 
pneumonia on surgical lung biopsy”. The main feature is fibrosis of the interstitium, 
leading to subpleural changes that are seen on chest x-ray and high-resolution CT 
thorax, and at an advanced stage will show a “honey-combing” pattern.   
In the early stages of IPF, infiltration with lymphocytes and plasma cells is 
present and as the disease progresses, fibroblasts appear and form a thick collagen mass. 
Further, the normal alveolar structure is destroyed and the typical scarring (illustrated in 
the figure 1.20) leads to empty cystic spaces in the terminal and respiratory bronchioles. 
(West, 2008b)  
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Fig. 1.20  
Alveoli with Pulmonary Fibrosis,  
accessed 4 April 2012, http://www.mountnittany.org 
Pulmonary fibrosis is scarring of the lung tissue between the alveoli and the blood vessels. If 
scarring is severe, O2 can not easily move from the air in the alveoli to the blood in the vessels. 
As a result, the blood does not deliver enough O2 to the body. 
 
 
Interstitial lung disease may arise from the use of medications such as bleomycin 
or amiodarone and can co-exist with autoimmune diseases such as rheumatoid arthritis, 
systemic lupus erythematosus and scleroderma, as these disorders can result in alveolar 
wall inflammation and fibrotic changes. (Ruppel, 1998) Therefore, other causes of 
interstitial lung disease should be excluded before the diagnosis of IPF is confirmed. 
Pulmonary function and lung imaging studies can be normal in early IPF. (King 
et al., 2000) However, as IPF advances, pulmonary function testing will show a non-
obstructive ventilatory defect with reduced FVC and FEV1 and normal FEV1/FVC ratio 
with reduced lung volumes (VC and TLC). Gas exchange is typically affected as the 
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alveolar-arterial pressure difference for O2 is increased. The reduction in DLCO may 
precede lung volume impairment. (Cooper et al., 2011)  
The blood volume of the pulmonary capillaries decreases in IPF due to vessels 
destruction by the fibrotic process. The hypoxemia that results from reduced DLco is 
usually mild at rest and will increase as IPF advances, where physiological VD and 
shunt are increased. Decreased pCO2 occurs due to increased ventilation to the alveoli. 
The work of breathing will also be increased in IPF as hyperventilation due to high 
respiratory rates is present. The most important cause of hypoxemia in IPF is V/Q 
mismatching, not anatomic shunting or reduced O2 diffusion. (Fishman, 2007) 
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Chapter 2 
 
METHODOLOGY 
 
2.1 Study Protocol 
 
 
The study involved the measurement of spirometry and CO diffusion capacity by 
the single-breath method in healthy subjects, patients with severe COPD and patients 
with interstitial lung disease (IPF and sarcoidosis patients with interstitial fibrosis) 
recruited from the Mercy University Hospital outpatient clinic. CO diffusion was 
measured with a standard 10 s breath-hold time and then repeated with an 8 s and 6 s 
breath-hold to determine if breath-hold time reduction led to significant differences in 
measured DLco. The Clinical Research Ethics Committee of the Cork Teaching 
Hospitals approved the protocol. After detailed explanation of the reasons for the study, 
informed consent was obtained  from the subjects for participation in the study . 
 
2.2 Study Criteria 
 
The inclusion and exclusion criteria were identified based on the the ATS\ERS  
guidelines for the DlcoSB measurement (MacIntyre et al., 2005). The ATS/ERS 
taskforce reports that some physiological and pathological changes can affect DLco 
measurements. Therefore, all subjects with asthma, obesity (BMI > 30), history of lung 
resection, anaemia (Hb<11 g/dL), recent pulmonary embolus (< 6 months), recent 
pulmonary haemorrhage (< 6 months), polycythemia, pulmonay oedema, pulmonary 
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vasculitis, left-to-right shunt, respiratory muscle weakness or thoracic deformity, severe 
cognitive dysfunction or psychiatric ilness and unstable comorbidity (uncompensated 
congestive heart failure, severe pulmonary hypertension, unstable angina or recent 
myocardial infarction) were excluded from the study.  (MacIntyre et al., 2005) 
The ATS/ERS guidelines also state that the use of supplemental O2 10 minutes 
before the DLco measurement and exercise 1 hour prior to testing testing can affect the 
pulmonary capillary blood volume and therefore the DLco value. Patients were 
instructed not to use supplemental O2 10 minutes and also not to perform exercise 
before measurements. The consumption of alcohol within 24 hours of testing has been 
reported to decrease DlcoSB measurements (MacIntyre et al., 2005; Wanger et al. 2005) 
as some fuel-cell CO analysers are sensitive to exhaled ethanol and ketones. Therefore 
patients were excluded if alcohol consumption was not avoided.  
Active smokers were excluded as COHb can decrease measured DLcoSB due to 
CO back presssure effects and the reported “anaemia effect” decreasing Hb binding 
sites for CO. (Viegi et al., 1998), and consequently all study subjects were non-smokers 
or ex-smokers for more than one year.  
 
2.3 Study Group 
 
 
 The study group consisted of 90 subjects who met the inclusion criteria. There 
were 30 healthy controls, 30 patients with COPD and 30 with interstitial lung disease 
(sarcoidosis with pulmonary fibrosis or IPF) all recruited from the Mercy University 
Hospital Outpatient clinic by a respiratory consultant. All subjects performed baseline 
Spirometry and DLcoSB in the respiratory laboratory of the Mercy University hospital 
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before recruitment, part of the routinely clinical respiratory assessment conducted by the 
respiratory team. 
The healthy controls had no history of airway or lung disease and had normal 
pulmonary function (FEV1/FVC > 70%, DLco > 80% predicted and KCO > 80% 
predicted).  
The COPD group had a pre-existing diagnosis of COPD and were included if 
FEV1/FVC was < 70% and FEV1 was 30-50% predicted, after inhaled bronchodilator. 
The ILD group had a pre-existing diagnosis of sarcoidosis stage two with pulmonary 
fibrosis or IPF and were included if FVC < 80% predicted, FEV1/FVC ratio >70% and 
DLcoSB < 80% predicted. (Miller et al., 2005) 
 
2.4 Measurements Protocol  
 
 
All measurements were performed in the Respiratory Laboratory of the Mercy 
University Hospital by the same certified Senior Respiratory Scientist with the subject 
seated and at rest. All measurements were performed between 9am and 1pm, as diurnal 
variation caused by a combination of changes in CO back pressure and diurnal variation 
in Hb concentration can affect the DLco measurements. (Cinkotai and Thomson, 1966; 
Frey et al., 1987) 
All subjects performed at first spirometry according to the ATS/ERS 
recommendations (Miller et al., 2005) allowing the FEV1, FVC and FEV1/FVC ratio 
assessment. Spirometry was recorded by a Jaeger Master-Screen PFT (Appendix B).  
After spirometry measurement the Hb was measured in all study subjects with 
an Hemocue Hb 201+ (Appendix A), necessary for the Hb value adjustment in all 
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following DLcoSB measurements, according to the ATS/ERS recommendations. 
(MacIntyre et al., 2005) 
The first DLcoSB measurement with a 10 s breath-hold time was performed in 
all subjects according to the ATS/ERS guidelines (MacIntyre et al., 2005), to ensure that 
every subject met the minimum cooperation requirements for the study. 
Before each DLcoSB measurement the analyser was zeroed against room air. 
Each subject was studied in the sitting position, at rest and with a nose clip in place. 
After a stable VT, each subject exhaled to RV and then inhaled a gas mixture containing 
0.28% CO, 9% He, 19% O2 and the remainder N2 to TLC. The software took into 
account the time delay between volume and gas fraction signals. When TLC was 
reached, a digital clock began timing the breath-hold, and after 10 s of breath-hold, the 
patient exhaled again to RV and a sample was collected for analysis. The breath-hold 
time was measured according to the Meade-Jones method (Jones and Meade, 1961) 
which assumed that the breath- hold time equals the time starting from 30% of the 
inspiration time to the middle of the sample collection time. The inspiratory time was 
defined when 90% of the VI was reached determining the end point.  
The DLco in this study was measured by the single breath method of Ogilvie et 
al. (1957) as modified by Jones and Meade (1961). The initial 750 ml of exhaled breath 
was discarded (representing the VD) and the next 750 ml of gas sample was used for 
analysis (or 500 ml if the subject’s VC was < 2L) (MacIntyre et al., 2005) The CO 
fraction was determined by an electrochemical analyser and the He by a thermal 
conductivity analyser.  
Two acceptable tests for each measurement were recorded, meeting the 
repeatability requirements of ATS/ERS recommendations (MacIntyre et al., 2005) of 
either being within 3 mL CO (STPD)
.
min
-1.
mmHg
-1
 of each other or within 10% of the 
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highest value. At least 4 minutes were allowed between tests to provide adequate 
elimination of test gas from the lungs and in the COPD group a 10 minutes interval was 
given according to the same guidelines. (MacIntyre et al., 2005). All subjects remained 
seated during this period. 
DLcoSB was calculated according to the standard equation: 
 
Eqt. 2.1 From MacIntyre et al., 2005. 
 
In equation 2.1 the VA is in ml STPD, t is the time of breath-hold and PH2O is the 
water vapour. The VA was measured from the He dilution as shown in the equation 2.2:  
 
      
Eqt. 2.2 From MacIntyre et al., 2005. 
 
If the subject met the recruitment inclusion criteria for the study, an informed 
consent was obtained by a respiratory consultant at the out-patients clinic of the Mercy 
University Hospital for participation in the study. 
After 1 hour of rest following the first DlcoSB measurement with 10 s breath-
hold, another measurement with breath-hold time reduced to 8 s was repeated followed 
again by 1 hour of rest until the last measurement with 6 s of breath-hold. All subjects 
remained in the waiting area of the Respiratory Laboratory of the Mercy University 
Hospital between the measurements.  
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In the COPD group all measurements were performed after inhaled 
bronchodilator therapy, which was not suspended for the study. It has been reported that 
the bronchodilator administration may increase the DlcoSB measurements up to 6% 
while affecting the VA and vasomotor tone. (MacIntyre et al., 2005) The bronchodilator 
effect was taken into consideration when the results were analysed. 
All measurements were part of the clinical respiratory assessment routinely 
conducted by the respiratory team. The only additional to the routine procedure was the 
breath-hold time reduction in the DLcoSB, which required two additional measurements 
to achieve the aim of this study. 
The figure 2.1 summarizes the present study design.  
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Fig. 2.1 Study Design 
All subjects performed 
Baseline Spirometry, Hb 
value and DLcoSB with 
10s breath-hold time, 
routinely clinical 
respiratory assessment 
 
Recruited from MUH 
OPD clinic: 
 30 Healthy 
controls 
 30 Severe COPD 
 30 ILD 
After 1 hour of rest from 
first DlcoSB 10 s breath-
hold measurement : 
 DlcoSB with 8 s 
breath-hold 
measurement 
 1 Hour rest seated 
 DlcoSB with 6 s 
measurement  
If patient 
available 
same day 
Clinical evaluation and 
inform consent was 
obtained by the respiratory 
If subject 
not 
available 
Returned 
schedule 
 Spirometry, Hb value and DlcoSB 10 s 
breath-hold measurement 
 1 Hour rest seated 
 DlcoSB with 8 s breath-hold measurement 
 1 Hour rest seated 
 DlcoSB with 6 s breath-hold measurement 
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2.5 Measurement Equipment 
 
 
Two types of equipment were used during the study, both in the Pulmonary 
Function Laboratory of the Mercy University Hospital. A brief description of each 
device, the basic principle of operation and its primary function in the study are given in 
this chapter. 
 
2.5.1 Jaeger Master Screen PFT 
 
 
This is a complete system for recording spirometry, pulmonary diffusion 
capacity and lung volumes.  
This system allows spirometry and CO-Diffusion by the single breath method 
measurement. Spirometry was performed in all subjects to assess FEV1, FVC and 
FEV1/FVC, followed by DLcoSB, KCO,VD, VA, FAHe and FAco assessment at three 
different breath-hold times of 10, 8 and 6 s with a gas mixture of 0.28% CO, 9% He, 
19% O2 and the remainder N2. (Appendix A). 
The volume and gas analysers used were calibrated daily according to the Irish 
Association Respiratory Scientists Quality Assurance guidelines (IARS, 2011). The 
Flow Measuring Sensor Calibration establishes the relationship between sensor-
determined values of flow or volume and the real flow or volume is named calibration. 
(Brusasco et al., 2005)  
Calibration was performed twice daily with volume checked by a 3L syringe, 
which was within 3% or 50 ml/s. This 3L syringe should read between 2.91 and 3.09 L 
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in calibration mode. Also linearity checks of flow rates between 2-12 L/s were 
performed weekly by adjusting the speed of the syringe in the flow sensing devices to 
cover the range of flows produced by the patient population, as low (2L/s), medium 
(6L/s) and fast flows (12L/s). The calibration syringe used was periodically leak tested 
at more than one volume up to it maximum and had a valid calibration certification.  
A second calibration was performed to the gas analyser. This calibration is called 
two-point calibration, where two gas concentrations are used. One gas concentration 
was used to zero the low end of the range and the second one was used to adjust the 
high end of the range. The main goal of this calibration is to adjust the analyser value in 
order to match the input of the known concentration of a gas. (IARS, 2011) This 
calibration was performed twice daily and was within ±1% of initial gas concentration. 
Stability is of major importance in analyzers, with minimum drift (< ± 0.5% of full 
scale) between calibration and testing, therefore the reading of the analysers was 
checked to detect any drift during testing. Quarterly gas analysers timing should be 
consistent with gas flow rate at a constant 200ml/min with a response time of less than 
30 s, which was checked during annual service. 
Prior to and after each measurement the gas analysers were zeroed and the gas 
calibration was performed at the time of the volume calibration. 
 
2.5.2 Hemocue Hb 201+ 
 
This is a portable system used for the determination of the total amount of 
haemoglobin in whole blood (Appendix B). The system consists of a specially designed 
analyzer with microcuvettes containing dried reagents. The haemoglobin measurement 
takes place in the analyzer, which follows the progress of the reaction until the end point 
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has been reached. This equipment allowed the quantitative determination of 
haemoglobin on every patient before the CO-diffusion measurement.   
No calibration process was necessary before each measurement. The system is 
factory calibrated against the haemiglobincyanide method, the international reference 
method for the determination of the haemoglobin concentration in the blood (Davis and 
Jungerius, 2010), and needed no further calibration. The analyzer has an internal quality 
control process that automatically verified the performance of the optronic unit during 
each measurement. 
 
2.6 Data storage and patient confidentiality 
 
All data pertaining to the study was stored in a computerized database on an 
encrypted departmental computer and backed up on CD and USB drives kept in a 
locked press in a locked office in the Respiratory Laboratory of the Mercy University 
Hospital. Data was available only to the principal investigator and co-investigators.  
Informed consent forms and other paper records pertinent to the study were kept 
by the principal investigator in a locked office. Personal data was stored, processed and 
analyzed in an anonymized format. This format did not include name, date of birth, 
address or medical record number of the subjects. 
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Chapter 3 
 
DATA ANALYSIS AND RESULTS 
 
3.1 Introduction 
 
This chapter presents the analysis and results of the data from this study. The 
study limitations regarding data collection and the statistical methods employed in the 
analysis are described first, followed by the details of the group characteristics and the 
data analysis. 
 
3.2 Study Limitations 
 
 
The main limitation of this study laid on the subject recruitment, as different 
groups were difficult to match for age and gender. This limitation justified the 
recruitment of 5 ex-smokers for the control group that, despite of being ex-smokers, met 
the inclusion and inclusion criteria for the control group, with normal spirometry 
(FEV1/FVC>70%, FEV1>80% pred and FVC>80%), normal DLcoSB (DLcoSB>80% 
predicted and KCO>80% predicted) and no history of respiratory impairment or lung 
disease. 
 Despite of the required maintenance of 10 s breath-hold and inspiration to TLC 
for the single breath method in the DLcoSB measurement, all subjects were able to 
perform all measurements in the study and meet the inclusion criteria. 
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3.3 Statistical Methods 
 
 
 In total, 36 variables were analysed. Kolmogorov-Smirnov testing was used to 
determine whether data were normally distributed. Comparisons between groups were 
made using two-tailed parametric testing or nonparametric testing, depending on 
whether data were normally distributed. Comparisons across groups were made using 
repeated measures analysis of variance (ANOVA) or Friedman test, depending on 
whether data were normally distributed. Statistical significance was assumed at p <0.05. 
Data were analysed using GraphPad Software (San Diego, CA). 
 
3.4 Group Characteristics 
 
Table 3.1 shows the anthropometric characteristics of the group, presented as 
mean and standard deviation (SD). The age of the subjects ranged between the 52.7 ± 
11.51 years in the control group, 63.5 ± 9.49 years in the COPD group and 61.9 ± 13.15 
years in the ILD group. Forty three subjects never smoked (48%) in contrast with 47 ex-
smokers (52%), with a predictably higher number of ex-smokers in the COPD group 
(100%). In the control group, 5 ex-smokers were identified and included in the study. 
Despite of ex-smokers they presented normal lung function confirmed by spirometry, 
normal DLcoSB measurements and no history of lung disease or respiratory problems. 
  
90 
 
 
 
Parameter  Control (n=30)  COPD (n=30)  ILD (n=30) 
Age (years)  53 ± 11.5  63.5 ± 9.5  62 ± 13 
Sex (M/F)  14/16  24/6  18/12 
BMI Kg/m²  27 ± 5  25.5 ± 3  26 ± 4 
Hb (g/dL)  13 ± 0.5  13.7 ± 1.2  13.6 ± 1 
Non/Ex-Smoker  25/5  0/30  18/12 
 
Table 3.1. Group Characteristics. Values are mean ± SD (where applicable) 
 
3.5 Spirometry measurements 
 
In the control group, the mean FEV1 % predicted and FEV1/FVC ratio were 
normal (Table 3.2).  
In the severe COPD group, the mean FEV1 % predicted was 37.02 ± 7.92 and 
FEV1/FVC ratio 47.0 ± 9.24, indicating severe airflow obstruction.  
In the ILD group, the mean FVC % predicted was 69.3 ± 14.60 and FEV1/FVC 
ratio 80.0 ± 10.88 showed a non-obstructive ventilatory defect. (Brusasco et al., 2005) 
All the sarcoidosis patients in the ILD group were clinically and radiological classified 
of stage two. 
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Parameter  Control (n=30)  COPD (n=30) ILD (n=30) 
FEV1 (L)  3.2 ± 0.653  1.05 ± 0.257  1.90 ± 0.627 
FEV1 % predicted  107.3 ± 12.04  37.02 ± 7.92  69.5 ± 17.61 
FVC (L)  3.81 ± 0.798   2.27 ± 0583  2.37 ± 0.735 
FVC % predicted  106.5 ± 11.78  63.1 ± 10.32  69.3 ± 14.60  
FEV1/FVC %  83.5 ± 4.88  47.0 ± 9.24  80.0 ± 10.88 
 
Table 3.2 Spirometry data by group. Values are mean ± SD 
 
3.6 DLcoSB by the single breath method 
 
All subjects were clearly instructed before and during testing by the same 
certified respiratory scientist, and had no difficulty in achieving two reproducible 
measurements to meet ATS/ERS criteria. (MacIntyre et al., 2005) The mean values for 
DLcoSB, VA and KCO measured with a 10 s breath-hold are described in the Table 3.3. 
Parameter/Group  Control (n=30)  COPD (n=30)  ILD (n=30) 
DLcoSB, mmol/min/kPa  8.10 ± 1.446  3.42 ± 1.522  3.47 ± 1.351 
DLcoSB % predicted  90.6 ± 8.07  39.8 ± 16.38  40.4 ± 13.02 
VA (L)  5.44 ± 0.897  4.33 ± 1.137  3.56 ± 0857 
VA % predicted  96.1 ± 10.10  73.9 ± 15.78  61.7 ± 12.38 
KCO, mmol/min/kPa  1.48 ± 0.183  0.79 ± 0.360  0.97 ± 0.312 
KCO % predicted  97.8 ± 10.96  57.6 ± 25.47  67.5 ± 18.07 
 
Table 3.3. CO Diffusion measurement by the Single Breath method with 10 s breath-hold. 
Values are mean ± SD 
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All measurements in the control group were normal (Table 3.4). In the severe 
COPD group, the DLcoSB % predicted was severely decreased (<40%) and in the ILD 
group, moderate impairment was present (40-60%). (Brusaco et al., 2005)  
The DLcoSB and DLcoSB % predicted measured in severe COPD and ILD 
patients was very similar and differed significantly from values measured in the control 
group. The group with ILD had the lowest VA and VA% predicted. The lowest KCO and 
KCO % predicted were found in the severe COPD group. 
 
3.7 DLcoSB measurement by the single breath method with breath-hold time 
reduction 
 
 
Each group performed the DLcoSB measurements at three different breath-hold 
times always by the same order of 10, 8 and 6 s, not randomised, with similar inspired 
and expired VC.  
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 Breath-Hold time  
  10 s  8 s  6 s  p value 
Control (n=30) 
DLcoSB mmol/min/kPa  8.10 ± 1.446  8.18 ± 1.428  8.02 ± 1.453  0.4431 
DLcoSB % pred  90.6 ± 8.07  91.9 ± 10.35  89.8 ± 8.56  0.3943 
KCO mmol/min/kPa  1.48 ± 0.183  1.51 ± 0.157  1.52 ± 0.208  0.1861 
KCO % pred  97.8 ± 10.96  99.0 ± 9.15  99.3 ± 12.65  0.4369 
COPD (n=30) 
DLcoSB mmol/min/kPa  3.42 ± 1.522  3.19 ± 1.387  2.96 ± 1.482  0.0003
*
 
DLcoSB % pred  39.8 ± 16.38  37.3 ± 15.14  34.7 ± 16.91  0.0019* 
KCO mmol/min/kPa  0.79 ± 0.360  0.75 ± 0.334  0.72 ± 0.360  0.0183* 
KCO % pred  57.6 ± 25.47  55.3 ± 24.39  53.2 ± 26.41  0.0489* 
ILD ( n=30) 
DLcoSB mmol/min/kPa  3.47 ± 1.351  3.50 ± 1.342  3.44 ± 1.392  0.5915 
DLcoSB % pred  40.4 ± 13.02  40.9 ± 12.84  40.1 ± 13.65  0.5251 
KCO mmol/min/kPa  0.97 ± 0.312  0.99 ± 0.298  0.99 ± 0.310  0.4921 
KCO % pred  67.5 ± 18.07  68.6 ± 16.31  68.2 ± 17.29  0.6177 
* Significance p<0.05 
Table 3.4 DLcoSB measurements at different breath-hold time. 
Values are mean ± SD. 
 
In the control and ILD group, there were no significant differences in DLcoSB 
and KCO measured using the three different breath-hold times 10, 8 and 6 s (p>0.05). 
However, in patients with COPD, there was a significant difference in the DLcoSB and 
KCO measurements across the 3 breath-hold times (p<0.05). As breath-hold time was 
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reduced from 10 to 8 and 6 s, the DLcoSB and KCO in severe COPD patients decreased 
gradually. The comparison of the DLcoSB and KCO measured in the three study groups 
at different breath-hold times is illustrated by Figures 3.1 and 3.2. 
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Fig. 3.1  
Comparison of DLcoSB at different breath-hold times across groups. 
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Figure 3.2  
Comparison of KCO at different breath-hold times across groups. 
 
Analysing the DLcoSB measurements at different breath-hold times was 
detected that in the severe COPD group, a significant difference in DLcoSB measured 
and DLcoSB% predicted with reduction of breath-hold from 10 to 8 s, however there 
was no significant difference detected in KCO measured from 10 to 8 s breath-hold time 
also stated by MacIntyre et al. (2005) previous report.  
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 Breath-hold time  
COPD  10 s  8 s  p value 
DLcoSB, mmol/min/kPa  3.42 ± 1.522  3.19 ± 1.387  0.0110* 
DLcoSB % pred  39.8 ± 16.38  37.3 ± 15.14  0.0242* 
KCO, mmol/min/kPa  0.79 ± 0.360  0.75 ± 0.334  0.0636 
KCO % pred  57.6 ± 25.47  55.3 ± 24.39  0.1410 
* Significant difference p<0.05 
Table 3.5 – Diffusion capacity in patients with COPD after 10 and 8 s of breath-hold time. 
Values are mean ± SD 
 
Table 3.6 describes the effect of reduction in breath-hold time on measured VD 
across the 3 groups. These measurements are relevant as VD is the air in conducting 
airways and alveolar space that does not participate in the gas exchange and will 
therefore produce changes in the DLcoSB measurement.  
 Breath-hold time  
 10 s 8 s 6 s p value 
VD ml 
Control (n=30) 
155.74 ± 7.681 155.3 ± 8.242 153.95 ± 8.628 0.0442
* 
VD ml 
COPD(n=30) 
161.42 ± 9.694 154.92 ± 7.822 155.58 ± 8.880 0.1563 
VD ml 
IPF (n=30) 
164.25 ± 11.046 150.12 ± 28.588 155.57 ± 2.235 0.0434
* 
*Significant difference p<0.05 
Table 3.6 Total dead space volume measured by the single breath method at different 
breath-hold times. Values are mean ± SD 
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The measured VD values at different breath-hold times were significantly 
different in the control and IPF group but no significant difference was found in the 
severe COPD group.  
Also, as He is used as a tracer gas to determine the initial CO concentration and 
measure VA in the single breath method by the dilution of He, the He and CO fraction 
were measured at different breath-hold times and mean results compared, in order to 
determine if the breath-hold time reduction will affect the fraction of He and CO in the 
final sample analysed. The results are presented in table 3.7.  
In the control and ILD groups, no significant difference was found in the FAHe 
measured as breath-hold time reduced, but significant differences were seen in the 
severe COPD group. Regarding the FAco, in all three groups studied there was a 
significant difference with breath-hold time reduction, which increased as the breath- 
hold time decreased in all study groups. 
 Breath-Hold time  
 10 s 8 s 6 s p value 
Control (n=30) FAHe 5.62 ± 1.192 5.40 ± 1.533 5.86 ± 0.700 0.4437 
 FAco 0.099 ± 0.048 0.107 ± 0.048 0.113 ± 0.034 <0.0001* 
COPD (n=30) FAHe 4.62 ± 0.801 4.78 ± 0.773 4.78 ± 0.794 0.0090* 
 FAco 0.093 ± 0.018 0.104 ± 0.035 0.109 ± 0.018 <0.0001* 
ILD (n=30) FAHe 5.16 ± 0.963 5.27 ± 0.828 5.33 ± 0.835 0.1345 
 FAco 0.101 ± 0.036 0.106 ± 0.019 0.116 ± 0.019 <0.0001* 
* Significance p<0.05 
Table 3.7 FAHe and FAco measured by the single breath method with different breath-
hold time. Values are mean ± SD 
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 The VA measurement depends on He dilution during the single breath method 
and also adjusts for the KCO calculation. Comparisons were made between the VA and 
VA % predicted in the three study groups as breath-hold reduced and table 3.8 reports 
the data obtained. There was no significant difference between the VA measured in all 
study groups with breath-hold time reduction, except in the measured VA % predicted in 
the COPD group as shown in figure 3.3, which significantly reduced with breath-hold 
time reduction. 
  Breath-hold time  
  10 s 8s 6s p value 
Control (n=30) VA 5.44 ± 0.897 5.43 ± 0.956 5.32 ± 0.928 0.1769 
 VA % pred 96.1 ± 10.10 96.0 ± 12.90 93.9 ± 10.43 0.2281 
COPD (n=30) VA 4.33 ± 1.137 4.35 ± 0.786 4.19 ± 0.761 0.3114 
 VA % pred 73.9 ± 15.78 72.6 ± 14.18 70 ± 14.25 0.0107* 
ILD (n=30) VA 3.56 ± 0.857 3.53 ± 0.858 3.47 ± 0.847 0.3050 
 VA % pred 61.7 ± 12.38 61.2 ± 12.88 60.2 ± 12.73 0.2499 
* Significance p<0.05 
Table 3.8 VA and VA% predicted measured by the single breath method with different 
breath-hold time. Values are mean ± SD 
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Chapter 4 
 
DISCUSSION OF RESULTS 
 
4.1 Anthropometric Data 
 
Previously published studies (Magnussen et al., 1979; Graham et al., 1985; 
Dressel et al., 2008) analysing the breath-hold time effect on DLcoSB measurement, 
presented different subject demographics compared to the present study and also the 
population age was younger when compared with the present study. The breath-hold 
time effect on DLcoSB measurement in previous reports (Magnussen et al., 1979; 
Graham et al., 1985; Dressel et al., 2008) was studied in patients with asthma, 
emphysema and cystic fibrosis, contrasting with COPD and ILD in the present study. 
The population size studied in the present study was also considerably larger than 
previous studies (Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008) 
(Table 4.1). 
Previous studies (Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 
2008) have analyzed the effect of DLcoSB breath-hold reduction in healthy subjects and 
patients with respiratory obstructive disorders, but not in non-obstructive pulmonary 
disorders such as ILD. The BMI was not calculated in any of the previous studies 
(Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008) and may be relevant 
in DLcoSB interpretation, as obesity, according to MacIntyre et al. (2005) increases the 
θVc and thus increases the DLcoSB value. In the present study, the mean BMI was 
increased in all 3 study groups, which may have led to a higher DLcoSB measured. 
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Studies 
(n=population number) 
Study Group/Age 
 
BMI Sex 
(M/F) 
Non/Ex/Smoker 
Magnussen et al., 1979 
(n=47) 
Normal 36.9 
Emphysema  61.7 
Asthma 47.1 
No data 
 
No data No data 
Graham et al., 1985 
(n=36) 
Normal 35±15 
Emphysema 54±11  
Asthma 40±16 
No data 9/6 
8/2 
8/3 
10/0/0 
1/6/3 
4/7/0 
Dressel et al., 2008 
(n=20) 
Normal 33±9  
CF 31±9 
No data 14/6 20/0/0 
Present Study 2012 
(n=90) 
Control 53±11.5 
COPD 63.5±9.5 
ILD 62±13 
27±5 
25.5±3 
26±4 
14/16 
24/6 
18/12 
25/5/0 
0/30/0 
18/12/0 
 
Table 4.1 Anthropometric data in 3 studies analysing the breath-hold time effect on the 
CO diffusion measurement by the single breath method 
Age in years, Body mass index in Kg/m
2
 (BMI), Sex (M/F = number of males and females in 
study population), Non/Ex/Smoker = number of Non-smokers, ex-smokers and smokers in the 
study population. Values are mean ± SD where applicable. 
 
In the present study, 62% of subjects were males and 38% of females and in 
previous studies (Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008) 
there was similar gender distribution of subjects studied. 
Regarding the population smoking habits of the present study, 48% never 
smoked in contrast with 52% ex-smokers, with a higher prevalence of ex-smokers on 
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the COPD group (100%). Similar population smoking habits were reported by Graham 
et al. (1985), despite the presence of three current smokers recruited in this study. 
Active smoking was an exclusion criterion in the present study, as COHb decreases 
DLco mainly due to the effects on CO back pressure and also decreasing the Hb binding 
sites for CO test gas. (MacIntyre et al., 2005) None of the other previous studies 
(Magnussen et al., 1979; Dressel et al., 2008) had smokers among the population. 
 
4.2 Spirometry measurements 
 
To identify and recruit the present study population, spirometry was performed 
in order to determine normal, obstructive and non-obstructive ventilatory defects. 
Spirometry was also performed in previous studies (Magnussen et al., 1979; Graham et 
al., 1985; Dressel et al., 2008) to determine the FEV1 and FVC of the population (Table 
4.2). 
The degree of airflow obstruction present in our study population in the severe 
COPD group may have been more severe when compared with previous studies 
(Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008). In Dressel et al. 
(2008), the CF group had mild to moderate airway obstruction (Pellegrino et al., 2005) 
and in Magnussen et al. (1979) and Graham et al. (1985), only the FEV1/FVC ratio was 
reported. However, the FEV1/FVC ratios of these two study groups were similar to the 
FEV1/FVC ratio of patients with severe COPD in the present study (Table 4.2).  
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Study 
(n=population number) 
Group FEV1% pred FVC% pred FEV1/FVC% 
pred 
Magnussen et al., 1979 
(n=47) 
Normal  
Emphysema   
Asthma 
No data  No data 77.1±14.2 
42.0±14.2 
46.6±14.1 
Graham et al., 1985 
(n=36) 
Normal  
Emphysema  
Asthma  
No data No data 81±9 
44±16 
54±7 
Dressel et al., 2008 
(n=20) 
Normal   
CF  
108±8 
69±28 
114±10 
84±5 
No data 
Present Study 2012 
(n=90) 
Control 
COPD  
ILD  
107.3 ± 12.04 
37.02 ± 7.92 
69.5 ± 17.61 
106.5± 11.78 
63.1 ± 10.32 
69.3 ± 14.60 
83.5 ± 4.88 
47.0 ± 9.24 
80.0 ± 10.88 
 
Table 4.2 Spirometry measurements in 3 studies analysing the breath-hold time effect on 
the CO diffusion measurement by the single breath method. Values are mean ± SD; 
n=number of subjects per group. 
 
Another important variable to consider is the bronchodilator effect on 
spirometric values measured, as well as on measured DLcoSB. In the present study, all 
spirometry and DLcoSB measurements were performed after inhaled bronchodilator, 
which may have led to a higher measured FEV1 and DLcoSB. Inversen et al. (1999) 
reported that in obstructive lung diseases after bronchodilator administration, the DLco 
may increase up to 6%. Similarly, Chinn et al. (1988) reported that bronchodilators may 
affect VA and the vasomotor tone. In the Graham et al. study, all patients avoided 
bronchodilators for at least 8 hours prior to testing. In the Dressel et al. (2008) study, no 
mention was made of inhaled bronchodilator use by the study population. 
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4.3 DLcoSB by the single breath method measurements 
 
4.3.1 DLcoSB in the control group 
 
The diffusion capacity is defined by Magnussen et al. (1979) as a conductance, 
consisting of transport of a gas divided by its pressure gradient between alveolar gas 
and capillary blood. 
Jones & Meade (1979) suggested that the decrease of DLcoSB with increasing 
breath-hold time, also reported in healthy subjects by Forster et al. (1954), will be less 
significant if corrections for the time of breathing were applied, thus allowing a better 
estimate of the alveolar-capillary diffusion barrier. No such corrections were made in 
the current study as was aimed to detect from DLcoSB measurements the resistance to 
diffusion across the alveolar capillary membrane and the influence of respiratory 
disorders on these measurements. 
The DLco in the present study was measured by the single-breath method of 
Ogilvie et al. (1957) modified by Jones and Meade (1961). The VA was measured 
during the single breath measurement from the dilution of He according to McGrath and 
Thomson (1959). The values obtained for the DLcoSB in the control group did not 
change with reductions of breath-hold time, as no significant differences were found 
between DLcoSB and KCO measured at 10, 8 and 6 s (p>0.05). These results were 
consistent with Graham’s previous study (Graham et al., 1985), which reported no 
significant difference (p>0.05) in DLcoSB values measured in healthy subjects at 
different breath-hold times (10, 5 and 2 s). On the other hand, other previous studies 
(Jones and Meade, 1961; Graham et al., 1980; Graham et al., 1981; Graham et al., 
1984) reported that DLcoSB increases during short and long breath-hold periods in 
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healthy subjects. Graham et al. (1985) used the three-equation calculation method for 
DLcoSB measurement, which differs from the conventional single Krogh equation used 
in the present study and all other studies previously mentioned (Magnussen et al., 1979; 
Dressel et al., 2008). Despite of different calculation methods, the results for DLcoSB 
measurements were similar in Graham et al. (1985) and the current study. Graham et al. 
(1985) justified the conflicted results for DLcoSB measured obtained with other 
previous studies, with the calculation method used (the three equation method), arguing 
that the increase in DLcoSB with short/long breath-hold times using the conventional 
single equation method in normal subjects will ignore CO uptake during inhalation and 
exhalation phases of the single breath manoeuvre, increasing errors as breath-hold time 
becomes shorter. The DLcoSB rise, according to Graham et al. (1985), may be 
explained by the inefficiency of the method rather than any impairment in lung 
diffusion. MacIntyre at al. (2005) suggests in the ATS/ERS statement that the three-
equation method can improve the accuracy of DLcoSB measurement, as it allows for 
volumes changes over time during inspiration and expiration when a measurement is 
being performed. This method might be more useful in subjects unable to rapidly inspire 
or expire rather than in healthy subjects. Despite the advantages of this calculation 
method, clinical experience with this approach is limited and need further 
standardization. 
The DLcoSB results of the control group in the present study (with considerably 
more subjects when compared to Graham et al. (1985) study), demonstrated no change 
in measured DLcoSB associated with breath-hold time reduction by the conventional 
single equation calculation method, suggesting that both methods may be suitable for 
DLcoSB assessment. The single equation method for DLcoSB calculation was also used 
in the other two previous studies (Magnussen et al.,1979 and Dressel et al., 2008), 
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where DLcoSB was reported to decrease with increasing breath-hold time in 14 healthy 
subjects (Magnussen et al., 1979) and in 10 healthy subjects (Dressel et al., 2008). 
Dressel et al. (2008) also observed a significant difference between the DLcoSB 
measured at 4, 6, 8 and 10 s in healthy subjects (p<0.05), however similarly to the 
present study, no significant difference was identified between the DLcoSB measured at 
8 and 6 s. The Magnussen et al. (1979) study measured DLcoSB at 10, 8, 6, 4 and 2 s 
and only reported a significant difference for DLcoSB measurements when breath-hold 
time was reduced to 6, 4 and 2 s in all groups, and in the emphysema group at 8 and 6 s. 
No significant effects were seen in DLcoSB measured at 10, 8 and 6 s for the healthy 
and asthma group. 
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Fig. 4.1  
DLcoSB measurement in 4 studies analysing the breath-hold time effect on DLcoSB 
measurements with different breath-hold times.  
Closed circles joined by solid lines represent DLcoSB mean measured different breath-hold 
times. Square brackets and p value indicate significant differences within DLcoSB values 
measured at different breath-hold times using two-tailed paired t test. 
 
These data strongly suggest that the breath-hold time for DLcoSB measurement 
could be reduced to 8 or 6 s as standard for healthy subjects, and still produce reliable, 
feasible and valid DLcoSB values. 
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4.3.2 DLcoSB measurement in obstructive and non-obstructive pulmonary 
disorders 
 
The diffusion capacity of the lung for a gas is directly proportionate to the size 
of the alveolar capillary membrane and inversely proportionate to its thickness. Any 
process that decreases the surface available for diffusion or thickens the alveolar-
capillary membrane will decrease the DLco.  
In obstructive pulmonary disorders such as COPD lung volumes are increased 
by air trapping with consequent hyperinflation, the alveolar walls and capillaries are 
typically destroyed reducing the total surface area available for gas exchange in the 
lung. According to MacIntyre et al., (2005), the CO during DLcoSB measurement may 
only reach better ventilated regions of the lung and therefore the measured CO uptake 
will be determined predominantly by the capacity of those regions. On the other hand, 
in asthma (West, 2008b), the DLcoSB is reported to be normal or increased possibly due 
to a more uniform distribution of the pulmonary blood flow. (Hyatt et al., 2003) 
In the severe COPD group of the present study, there were significant 
differences in the DLcoSB and KCO (p<0.05) measured at 10, 8 and 6 s of breath-hold, 
suggesting a correlation of the DLcoSB with breath-hold time reduction when severe 
airway obstruction is present. Analysis of results indicated that less than 10 s of breath-
hold time was insufficient to allow complete diffusion of inspired CO. This might be 
explained either by the alveolar destruction present in this disorder decreasing the 
surface area for diffusion or by air trapping preventing complete CO washout. A 
significant difference between the DLcoSB measurement at 10 and 8 s was also noted; 
however, there was no significant change in KCO. 
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Dressel et al. (2008) demonstrated no influence of breath-hold time on DLcoSB 
in 10 patients with CF (figure 4.1). In contrast, Graham et al. (1985) found that DLcoSB 
decreased with breath-hold time reduction in patients with asthma and emphysema. The 
authors explained this finding by suggesting stratification of inhaled gas within the gas-
exchanging lung regions prior to the effective alveolar-capillary gas exchange. 
Equilibration of inspired and alveolar gas might take longer when airflow obstruction is 
present. (Chang et al., 1973) The longer time needed for complete mixing of CO with 
alveolar air may cause a reduction in measured DLcoSB when airflow obstruction is 
present. The results obtained by Graham et al. (1985) are similar to the results obtained 
in the present study for patients with severe COPD, despite of the different calculation 
method used for DLcoSB. Graham et al., (1985) also reported that a lower DLcoSB at 
shorter breath-hold time when airway obstruction is present, may lead to higher 
resistance to gas exchange due to a longer path that the inspired gas has to diffuse to 
reach the alveolar-capillary membrane. 
Magnussen et al. (1979) similarly observed that DLcoSB decreased with breath-
hold time reduction in patients with emphysema; however in patients with asthma, the 
DLcoSB results were comparable to normal subjects and increased with the breath-hold 
time reduction. Magnussen et al. (1979) suggested that the reduction of DLcoSB with 
lower breath-hold time in airway obstruction may be due to loss of gas exchange area 
but also to stratification of the gases mixing in the lung. Sikand et al. (1976) and 
Kawashiro et al. (1976) also suggested that gradients of intrapulmonary gas 
concentration are better explained by the stratified inhomogeneity present in the lungs. 
Magnussen et al. (1976) and Nieding et al. (1978) demonstrated that in patients with 
emphysema, stratification is an important factor limiting intrapulmonary gas mixing. As 
emphysema is a key feature of COPD, can also be inferred that the decreased DLcoSB 
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in the present study with breath-hold time reduction in the severe COPD group, may be 
due to poor He and CO intrapulmonary mixing limited by stratification. 
All subjects in the present study population were non-smokers or ex-smokers, 
which minimized the “CO back pressure” influence in DLcoSB measurements. 
According to Qutayba et al. (2005), COHb exists in small concentrations, around 1% in 
non-smokers but increases with repeated DLcoSB measurements, up to 10% or higher 
in chronic smokers. If DLcoSB is not adjusted for the COHb increase, the so-called 
“anaemia effect” can occur, reducing the effective Hb available to bind with CO in the 
test gas mixture, leading to DLcoSB underestimation. The DLcoSB measured can be 
underestimated if COHb is not adjusted for the ambient alveolar CO concentration 
before each single breath measurement, which is assumed to be zero but is increased in 
smokers according to Graham et al. (2002). Abstinence from cigarette smoking 24 
hours prior to DLcoSB testing can help to reduce COHb and consequent CO back-
pressure (MacIntyre et al., 2005). In the present study, all subjects were non-smokers or 
ex-smokers, which eliminated the effect of CO back pressure and the need for COHb 
correction during DLcoSB measurement.  
To summarise the results of our study and previous studies in relation to COPD, 
the breath-hold time for DLcoSB measurement in patients with COPD should be 
retained at 10 s and certainly should not be reduced to less than 8 s.  
The main reason to assess the effect of breath-hold time reduction on measured 
DLcoSB in patients with ILD was the absence of published data in this clinical context. 
We decided to study patients with sarcoidosis with pulmonary fibrosis and patients with 
IPF to evaluate the effect of the breath-hold time reduction when thickening of the 
alveolar-capillary membrane is present. 
In the ILD group, no significant difference was observed in DLcoSB and KCO 
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measured at 10, 8 and 6 s (p>0.05), despite the expected baseline reduction of DLcoSB. 
The mean DLcoSB % of predicted was 40.4 ± 13.02 for 10 s of breath-hold in the ILD 
group, indicating a moderate to severe impairment of diffusing capacity according to 
ATS/ERS criteria. Despite of a similar impairment degree of DLcoSB in patients with 
ILD compared with the severe COPD group, there was no significant difference 
between the DLcoSB and KCO measured at 10, 8 and 6 s in the ILD group. From the 30 
patients of the ILD group, 15 were clinically diagnosed stage two sarcoidosis patients 
with radiologic hilar adenopathy and parenchymal infiltration reflecting a non-
obstructive ventilatory defect on spirometry measurements (table 3.2) and also moderate 
impairment was present when DLcoSB and KCO were measured (40-60%). (Brusaco et 
al., 2005)  
Roughton and Forster (1957) reported that the resistance to diffusion of a gas in 
the lung will depend of the resistance offered by the alveolar-capillary membrane to the 
gas transferred and also on the resistance of the chemical combination with Hb. In other 
words, the resistance to diffusion of CO in the lung will depend of the features of the 
alveolar-capillary membrane and the quantity of Hb in the pulmonary capillaries 
available to combine with CO. Therefore, the DLco measured will depend of membrane 
factors and circulatory factors. According to Weinberger et al. (1980) the alveolar-
capillary membrane can be quantitatively impaired referring to the surface area per lung 
volume, and qualitatively impaired, referring to a change in the membrane thickness. In 
ILD, thickening of the alveolar wall will increase the resistance to diffusion of gas 
across the alveolar-capillary membrane. However, Weinberger et al. (1980) reported 
that the relative contribution of the membrane thickness in lowering the DLco in 
disorders such as interstitial fibrosis may be overestimated. Other pathological changes, 
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like alteration of alveolar architecture, can reduce the alveolar-capillary membrane 
surface area for gas exchange, which appears to be more relevant to reductions in DLco.  
When breath-hold time was reduced from 10 to 8 and 6 s, no significant 
difference was observe in measured DLcoSB as shown in figure 3.1. These results 
suggested that despite of quantitative and qualitative changes in the alveolar-capillary 
membrane in patients with ILD, breath-hold time reduction will not produce significant 
changes in the DLcoSB measured, similarly to the control group already discussed. 
McNeill et al. (1958) reported that in pulmonary fibrosis due to sarcoidosis, the 
membrane component (DM) is significantly more reduced than capillary volume and 
Johnson et al. (1961) observed that the reduction of DM was the major change and Vc 
was relatively unaffected. According to Hamer (1963), the reduction in DM after several 
years of pulmonary infiltration may be due to fibrotic changes reducing the area 
available for diffusion and Vc reduction is only commonly observed in patients with 
prolonged disease. Reduction of the Vc was not observed without DM reduction, which 
suggests that Vc changes are more frequently associated with increased severity of 
fibrosis. Additionally, Marshall et al. (1958) suggested that in pulmonary sarcoidosis, 
diffusion changes are mainly due to perivascular lesions rather than relative changes in 
the mechanical properties of the lungs. 
The loss of the alveolar-capillary membrane surface area in patients with COPD 
through destruction of alveolar walls when compared with the loss of alveolar-capillary 
membrane surface area in patients with ILD through scarring and thickening of the 
alveoli, seemed to generate more significant changes in DLcoSB measurement with 
reduced breath-hold time. This suggests that airflow obstruction may be more 
responsible for decrease of the DLcoSB measured with breath-hold time reduction. 
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Krogh (1915) originally reported that the DLco decreased with VA reduction 
until FRC was reached and the progressive decrease in the size of the membrane would 
explain this change. Other studies (Ferris, 1978) have confirmed Krogh’s observation 
and similarly noted that changes in VA are responsible for DLco measurement 
variability. Forster Farhi, L. Tenney, S. (1987) suggested that: “If the normal lung was a 
collection of spheres and if DLcoSB was directly proportional to the surface area of the 
spheres, then DLcoSB would vary with alveolar volume”. In contrast, Cotton and 
Qutayba et al., (2005) suggested that the capillary surface area is preserved with a 
decreased VA, as the alveolar-capillary membrane tends to fold, rather than shrink, 
when lung volume decrease.  
In the present study, the VA measured by He dilution during breath-hold in the 
DLcoSB measurement was reduced in patients with severe COPD and ILD, with a 
higher reduction in patients with ILD. As breath-hold time was reduced in DLcoSB 
measurements from 10 to 8 and 6 s, no significant difference was observed in VA 
measured in all study groups, except in the measured VA % predicted in the severe 
COPD group. According to Fishman in Farhi and Tenney (1987), the resistance of the 
vascular alveolar segment decreases with VA reduction from TLC to FRC, while 
pulmonary capillaries widen and Vc increases. Graham et al., (2002) reported that a VA 
reduction from TLC to 50% of IC will decrease DLcoSB minimally. Fishman (2007) 
states that DLco decreases with reduction of VA along with the reduction of available 
surface area and Vc for diffusion. The idea from Fishman in Farhi and Tenney (1987) 
that the Vc may increase with VA reduction while the capillary bed is still preserved 
may help to understand why in the present study, even with a low VA in the ILD group, 
the breath-hold time reduction did not produce significant changes in measured 
DLcoSB and KCO (p<0.05). This might suggest that 6 s of breath-hold time can be as 
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valid as 10 s to measure DLcoSB in patients with ILD, in the absence of concomitant 
airflow obstruction. 
During the single breath method to measure DLco, after breath-hold and during 
expiration, the first 750 ml of volume is discarded and the next 750 ml of gas is used for 
analysis. In the severe COPD group in the present study, due to low VC (<2L) only 500 
ml was collected for sampling. (MacIntyre et al., 2005) The first 750 ml of expired 
breath contains gas from the anatomical VD (volume in the conducting airways that does 
not participate in gas exchange) and instrumental VD (mouthpiece, filters and 
connections of the system). (MacIntyre et al., 2005) As VD corresponds to the portion of 
expired volume in the DLcoSB measurement that does not participate effectively in gas 
exchange during breath-hold, was decided to investigate if the measurement of VD was 
affected by the breath-hold time reduction. 
Therefore, VD was measured at different breath-hold times (10, 8 and 6s) and 
results are presented in Table 3.6. Significant differences were found in the control and 
ILD groups when breath-hold time was reduced. However, no significant difference was 
found in the VD measured in the severe COPD group.  
According to Morton et al., (1965) the alveolar gas sample, when contaminated 
by VD gas, may lead to CO uptake underestimation. Was observed that in the control 
group and patients with ILD, breath-hold time reduction led to a significantly reduced 
VD (p<0.05) however the measured DLcoSB and KCO were not affected. Therefore, the 
effect on VD was not significant. On the other hand, no significant difference was found 
in the severe COPD group for the VD measured at different breath-hold time and yet, 
significant differences were detected in the measured DLcoSB and KCO with breath-
hold time reduction.  
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Morton et al. (1965) stated that the initial and final CO concentrations in 
DLcoSB measurement are affected by dead space washout, as initial CO is determined 
by the dilution of He. If dead space is not efficiently washed out, the final concentration 
of He in the expired sample will be higher and lead to higher initial CO concentration. 
Morton et al. (1965) observed patients with normal and impaired alveolar gas 
distribution and noted that differences in expired volumes led to less dilution of dead 
space He and CO. He also noted that the size of the expired sample could have been 
reduced by air trapping since subjects with uneven alveolar ventilation had severe 
obstructive airways disease. Based on these data, it is not clear whether the time for 
complete washout of He and CO in the severe COPD group was sufficient to provide 
complete elimination of the gas mixture in the alveolar space between measurements 
and thus avoid changes in measured DLcoSB.  
The table 3.7 shows that there were significant differences (p<0.05) in the FAHe 
and FAco alveolar fraction measured with breath-hold time reduction from 10 to 8 and 6 
s in the severe COPD group, as reported by Morton et al. (1965). This might have been 
a significant factor accounting for the reduction in measured DLcoSB at progressively 
reduced breath-hold time in patients with severe COPD. However, in the control and 
ILD groups no significant difference was found for the FAHe measured, despite of a 
similar FAco difference. This results indicated that the time between measurements for 
the He washout from the alveolar space for the control and ILD group was adequate, as 
per ATS/ERS guidelines (MacIntyre et al., 2005) 4 minutes between manoeuvres and 1 
hour between measurements. In the severe COPD group, the time recommended of 10 
minutes in between DLcoSB manoeuvres and 1 hour in between measurements may not 
to be sufficient for He and CO alveolar washout as significant differences were found. 
This might suggest that time in between measurements should be extended when severe 
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airflow obstruction is present, as the expired sample is reduced by air trapping in 
COPD, prolonging the test gas mixture washout and interfering with the DLcoSB 
measured. (Hyatt et al., 2003) 
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Chapter 5 
 
CONCLUSION 
 
5.1 Conclusions / Recommendations 
 
 
The present study is the largest report analysing the effect of breath-hold time on 
measured DLco measurement by the single breath method to date. Furthermore, our 
data show some conflicting results when compared to previously published reports 
(Magnussen et al., 1979; Graham et al., 1985; Dressel et al., 2008)  
The present study indicates that in healthy subjects, measured DLcoSB and 
KCO is not affected with breath-hold time reduction, as has been previously reported by 
Magnussen et al. (1979) and Graham et al. (1985). However, in the presence of severe 
COPD, the DLcoSB is influenced by breath-hold time, where DLcoSB and KCO 
significantly decrease with breath-hold time reduction. These data leaded to conclude 
that in patients with airflow obstruction, the time necessary for mixing of inspired gas 
with alveolar gas will reduce the CO uptake when breath-hold time was decreased from 
10 s, as suggested by the ATS/ERS guidelines (MacIntyre et al., 2005).  
In contrast, in patients with ILD, despite moderate to severe baseline DLcoSB 
impairment, there was no significant influence of breath-hold time reduction on 
measured DLcoSB, suggesting that in patients with ILD who are unable to breath-hold 
for 10 s, DLcoSB measurement using a 6 second breath-hold time may provide an 
acceptable and clinically meaningful result. 
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Was also conclude that the washout time, necessary to clear He and CO inhaled 
in each DLcoSB measurement, is of major importance to produce valid results, as 
impaired clearance of these gases from the alveolar space will interfere with the final 
results for measured DLcoSB.  
 Can be useful further studies involving the population size increase of each 
analysed group to determine whether results remain consistent, studying also the effect 
of breath-hold time reduction on measured DLcoSB in patients with other types of ILD, 
as well as, the effect of breath-hold time reduction on measured DLcoSB in patients 
with different COPD stages. Also assess the dyspnoea degree of the study population 
using the Borg Scale at the time of the DLcoSB measurements can provide useful 
information. Furthermore, arterial blood gases assessment in addition to DLcoSB 
measurements in patients with obstructive and non-obstructive ventilatory disorders 
could help to assess ventilation/perfusion mismatching and its influence on DLcoSB 
measurements. Day to day variability of the DLcoSB measurements should as well be 
considered in further studies. 
 
5.2 Publications 
 
An abstract for this work has been accepted for poster discussion at the 
European Respiratory Society meeting and was presented in Vienna on September 2012. 
Abstracts will be submitted to the Irish Thoracic Society (2012) and American Thoracic 
Society (2013) meetings and we hope to submit a manuscript to a peer-reviewed journal 
for publication, after review of the thesis. 
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Appendices 
 
Appendix  A 
 
JAEGER MASTERSCREEN PFT  
 
 Power supply 
Input range 230V, 50/60 Hz, 1.8 A 
 
 Dimensions 
Length*Width*Height: 78 cm * 100 cm * 155 cm  
 
 Technical data 
 
Flow measurement JAEGER pneumotacograph  
Range 0 ± 20 l/s  
Accuracy 0.2 - 12 l/s ± 2%  
Resistance <0.05kPa/(l/s) at 10l/s  
 
Volume determination digital integration  
Range 0- ± 20 l  
Accuracy 5 ml  
 
Mouth pressure piezo-resistive  
Range ± 20 kPa  
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Accuracy < ± 2 %  
 
CO analyser electrochemical cell  
Range 0 - 0.4 %  
Accuracy 0.0003 %  
 
He analyser thermal conductivity  
Range 0 - 9.5 %  
Accuracy 0.05 %  
Calibration CAL-Pack, automatically  
 
 Premixed gas 
Diff-SB and Diff-RB 0.28 % CO, 9 % He, 19 % O2, Balance N2 
 
 Computer 
Pentium computer, printer and monitor on an ergonomic, smoothly-running 
trolley. Lab Manager Software version 5.3.0.4 
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Appendix  B 
 
HEMOCUE HB 201+ 
 
 Parameters recorded 
Hb g/L 
 
 Performance Hb 
Measuring Range: 0-256 g/L 
 
 Dimensions (HxWxD) 
85x160x43 mm 
 
 Weight 
350 gr 
 
 Power supply 
4 Batteries type AA 0r R6, 1.5 V 
 
 Environmental conditions  
Operating temperature: 15-30
0
C 
Analyser Storage Temperature: 0-50
0
C 
Microcuvettes Storage Temperature: 15-30
0
C 
Relative Humidity: should not be operated at high humidty (i.e.>90% non-
condensing) 
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Appendix  C 
 
UNIVERSITY COLLEGE CORK 
 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH PROTOCOL 
Section A 
 
Protocol Number: ____________________ Patient Name: _________________             
 
Title of Protocol: Effect of reduction of breath-holding time in the single-breath 
method to assess carbon monoxide diffusing capacity.  
 
Doctor Directing Research: Dr. Terry O’Connor, Mercy University Hospital, Cork 
Phone: 021-4935325 
 
You are being asked to participate in a research study. The doctors at University 
College Cork study the nature of disease and attempt to develop improved methods of 
diagnosis and treatment. In order to decide whether or not you want to be a part of this 
research study, you should understand enough about its risks and benefits to make an 
informed judgment. This process is known as informed consent. This consent form 
gives detailed information about the research study, which will be discussed with you. 
Once you understand the study, you will be asked to sign this form if you wish to 
participate. 
 
 
Section B 
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I. NATURE AND DURATION OF PROCEDURE(S): 
  
This study aims to investigate alternative ways of performing a test that we use 
to assess your lung function. During this test, you are asked to perform spirometry and 
CO-Diffusion which measure the lung volumes and gas exchange. CO-Diffusion 
requires that you empty all the air in your lung and take a deep breath during which a 
small amount of carbon monoxide will be inspired. When your lung is full you will 
have to hold your breath for 10 s followed by a complete expiration. This procedure is 
part of our routine assessment of lung function and is performed routinely 
irrespective of your participation in the study. The additional testing that follows is 
the study part of the assessment. After 1 hour of rest you will be asked to repeat the 
CO-Diffusion test but holding your breath for 8 s, followed again by 1 hour of rest until 
the last measure with 6 s of breath-holding. This test will be conducted in the 
Respiratory Laboratory of the Mercy University Hospital and by a qualified Senior 
Respiratory technician also involved in this study. All records involving your 
participation in this research will be kept in complete confidentiality. 
 
II. POTENTIAL RISKS AND BENEFITS: 
 
All the measurements involved in this study are part of the clinical respiratory 
assessment routinely conducted by the respiratory team. The amount of carbon 
monoxide inspired during the measurements will be according with the American 
Thoracic Society and the European Respiratory Society guidelines minimizing any risk 
of injury to patients. This research may influence future guidelines for the performance 
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of the CO Diffusion test and may reduce the breath-holding time required to perform 
this test. 
 
III. POSSIBLE ALTERNATIVES: 
 
You may choose not to participate in this research protocol or withdraw from the 
study at any time after consenting to participate. You will be given a copy of the consent 
form for your records. 
 
Section C                                                                    AGREEMENT TO CONSENT 
 
The research project and the treatment procedures associated with it have been 
fully explained to me. All experimental procedures have been identified and no 
guarantee has been given about the possible results. I have had the opportunity to ask 
questions concerning any and all aspects of the project and any procedures involved. I 
am aware that participation is voluntary and that I may withdraw my consent at any 
time. I am aware that my decision not to participate or to withdraw will not restrict my 
access to health care services normally available to me. Confidentiality of records 
concerning my involvement in this project will be maintained in an appropriate manner. 
When required by law, the records of this research may be reviewed by government 
agencies and sponsors of the research. 
 
I, the undersigned, hereby consent to participate as a subject in the above 
described project conducted at the Cork Teaching Hospitals. I have received a copy of 
this consent form for my records. I understand that if I have any questions concerning 
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this research, I can contact the doctor(s) listed above. If I have further queries 
concerning my rights in connection with the research, I can contact the Clinical 
Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 Little 
Hanover Street, Cork. 
 
After reading the entire consent form, if you have no further questions about 
giving consent, please sign where indicated. 
 
 
Doctor:                                               
Signature of Subject:       
            
 
Witness:                                              Date:                            Time: __________  
